<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>280</serviceExecutionTime><Trial id="132099"><TitleDisplay>Comparison of the Efficacy of Two Therapeutic Regimens for Primary Nocturnal Enuresis; Oxybutynin Plus Desmopressin Versus Desmopressin in Pediatric Patients</TitleDisplay><TitleOfficial>Comparison of the efficacy of two therapeutic regimens for primary nocturnal enuresis; oxybutnin plus desmopressin versus desmopressin in pediatric patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT201301117892N4</Identifier><Identifier type="Other">9158</Identifier></Identifiers><Indications><Indication id="2022">Enuresis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>desmopressin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>desmopressin</Name></Intervention><Intervention type="InterventionPrimary"><Name>oxybutynin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="25107" type="Company"><TargetEntity id="5035529437" type="organizationId">Tabriz University of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="2022" type="ciIndication"><TargetEntity id="10014928" type="MEDDRA"/><TargetEntity id="D004775" type="MeSH"/><TargetEntity id="-1255605797" type="omicsDisease"/><TargetEntity id="353" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25107">Tabriz University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2012-08-31T00:00:00Z</DateStart><DateChangeLast>2017-07-13T04:09:54Z</DateChangeLast><DateAdded>2013-05-21T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tabriz Medical University ;  Childrens hospital-sheshgelan st. ; Tabriz ; East-Azarbayjan ; Iran, Islamic Republic Of ;</Affiliation><Email>azarfar132@yahoo.com</Email><Name>Anoosh Azarfar</Name><Phone>984116584153</Phone></Contact><Contact type="Public contact"><Affiliation>Tabriz university of medical sciences ;  No. 57, Azimi alley, North Tavanir, Abbasi street ; Tabriz ; East Azarbaijan ; Iran, Islamic Republic Of</Affiliation><Email>hemmati.mehdi@gmail.com</Email><Name>Mehdi Hemmati</Name><Phone>984116584305</Phone></Contact><Contact type="Public contact"><Affiliation>Vice chancellor for research, Tabriz University of Medical Sciences, Daneshgah square Tabriz East-Azarbayjan Iran, Islamic Republic Of</Affiliation><Email>aostadrahimi@yahoo.com</Email><Name>Alireza Rahimi</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age of 5 to 18 year old patients with primary nocturnal enuresis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;To have neurogenic bladder&lt;/li&gt;&lt;li&gt;CNS disorders&lt;/li&gt;&lt;li&gt;Secondary nocturnal enuresis&lt;/li&gt;&lt;li&gt;Occurrence of drug side effects&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Frequency of nocturnal urination in a week: using a questionnaire</Description><Timeframe>Weekly for 12 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The main objective of the trial was to compare the efficacy of two therapeutic regimens for primary nocturnal enuresis ie, oxybutynin plus desmopressin versus desmopressin in pediatric patients [&lt;ulink linkType="Reference" linkID="1424002"&gt;1424002&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In a unicentral randomized trial 60 patients with age of 5 to 18 years from both genders with primary nocturnal enuresis referring to the nephrology clinic of Tabriz Childrens hospital would be assigned in two equal-sized groups to receive combination of nasal desmopressin and oxybutynin or nasal desmopressin alone. Desmopressin spray would be administered one puff/night for all the patients and oxybutynin 0.5 to 1 tablet three times a day as needed. A period of 3 months after drug consumption patients in the groups would be evaluated in terms of presence of nocturnal enuresis [&lt;ulink linkType="Reference" linkID="1424002"&gt;1424002&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Tabriz Children's Hospital</Name><Address1>Tabriz</Address1><Address2>East-Azarbayjan</Address2><CountrySubDivision>East-Azarbayjan</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Urinary incontinence</Disease><PatientSegments><PatientSegment><PatientSegment id="8707">Pediatric Subjects with Urinary Incontinence</PatientSegment><SubSegments><SubSegment id="8712">Pediatric subjects with nocturnal enuresis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT201301117892N4</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Urinary incontinence" id="14670"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Urinary incontinence" id="13507"><Criterion>Pediatric Subjects with Urinary Incontinence</Criterion><SubCriteria><SubCriterion disease="Urinary incontinence" id="13509">Pediatric subjects with nocturnal enuresis</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Urinary incontinence" id="15202"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Urinary incontinence" id="15212"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Urinary incontinence" id="15228"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Urinary incontinence" id="26761"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Urinary incontinence" id="15192">Subjects with Urge Incontinence/Overactive Bladder</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2013-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>6.03 Months</EnrollmentPeriod><EnrollmentRate>9.95 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-05-21T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2013-11-28T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="136495"><TitleDisplay>Dialysis Exchange Free Treatment for Peritonitis in Peritoneal Dialysis, a Safety Trial</TitleDisplay><TitleOfficial>Use of Icodextrin® Dialysate with an exchange free period in the initial treatment of peritoneal dialysis associated peritonitis: A Pilot Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">ACTRN12608000006347</Identifier><Identifier type="Other">HREC NTX/07/10/103</Identifier></Identifiers><Indications><Indication id="452">Peritonitis</Indication></Indications><BiomarkerNames><BiomarkerName id="213" role="Therapeutic effect marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="3475" role="Therapeutic effect marker" type="Biochemical">Urea</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>icodextrin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="14437" type="Company"><TargetEntity id="4295903531" type="organizationId">Baxter International Inc</TargetEntity></SourceEntity><SourceEntity id="452" type="ciIndication"><TargetEntity id="K65" type="ICD10"/><TargetEntity id="10034674" type="MEDDRA"/><TargetEntity id="D010538" type="MeSH"/><TargetEntity id="-1837137483" type="omicsDisease"/><TargetEntity id="2483" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="14437">Baxter International Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2010-02-03T00:00:00Z</DateStart><DateChangeLast>2018-07-17T05:17:56Z</DateChangeLast><DateAdded>2013-06-03T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Department of Renal MedicineLevel 15- support BuildingAuckland City HospitalPrivate Bag 92024Auckland, New Zealand</Affiliation><Email>mahay@adhb.govt.nz</Email><Name>Maha Yehia</Name><Phone>6421737276</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with peritonitis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Removal of Tenchkoff catheters</Description></Measure><Measure><Description>Time to resolution of peritonitis</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Death</Description></Measure><Measure><Description>Hospitalization</Description></Measure><Measure><Description>Monitoring of systemic and peritoneal markers of inflammation and fibrosis by blodd and peritoneal fluid testing</Description></Measure><Measure><Description>Relapse of peritonitis serum urea and creatinine by lab testing technique</Description></Measure><Measure><Description>Failure by documenting transfer to hemodialysis ultrafiltration capacity- by weighing the peritoneal effluent</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to assess the use of icodextrin dialysate with an exchange free period in the initial treatment of peritoneal dialysis associated peritonitis [&lt;ulink linkType="Reference" linkID="1432197"&gt;1432197&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive intraperitoneal icodextrin (2500 mls of 7.5%) for dialysis in conjunction with dry exchanges for 2 days post peritonitis onset. Thereafter patients continue as per standard treatment. Intraperitoneal antibiotics are added to one exhange/day [&lt;ulink linkType="Reference" linkID="1432197"&gt;1432197&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="New Zealand"><Sites><Site><Address1>Auckland </Address1><Contacts/></Site><Site><Address2>Auckland</Address2><CountrySubDivision>Auckland</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>End stage renal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7704">Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7719">Subjects with Other Complications of Chronic Kidney Disease</PatientSegment><SubSegments><SubSegment id="7724">Subjects with dialysis complications</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="20180">Subjects by disease severity</PatientSegment><SubSegments><SubSegment id="7702">Subjects with stage 5 chronic kidney disease/end stage renal disease(ESRD)</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Intra-abdominal Infections</Disease><PatientSegments><PatientSegment><PatientSegment id="8653">Subjects with Peritonitis</PatientSegment><SubSegments><SubSegment id="8655">Subjects with secondary peritonitis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1011">Australian New Zealand Clinical Trials Registry (ANZCTR)</Name><Identifiers><Identifier type="Secondary Organisational">ACTRN12608000006347</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Intra-abdominal Infections" id="14708"><Endpoint>Assessment of Clinical Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22570"><Endpoint>Assessment of dialysis</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22573">Assessment of vascular access</SubEndpoint><SubEndpoint disease="End stage renal disease" id="22574">Assessment of dialytic complications</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="End stage renal disease" id="22595"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Intra-abdominal Infections" id="14708"><Endpoint>Assessment of Clinical Response</Endpoint><SubEndpoints><SubEndpoint disease="Intra-abdominal Infections" id="14710">Clinical failure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Intra-abdominal Infections" id="14722"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22509"><Endpoint>Assessment of Urinary Protein Excretion/Proteinuria</Endpoint><SubEndpoints><SubEndpoint disease="End stage renal disease" id="22511">Assessment of proteinuria/albuminuria/macroalbuminuria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22513"><Endpoint>Assessment of Urine Creatinine</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="End stage renal disease" id="22543"><Endpoint>Assessment of lipid profiles</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Intra-abdominal Infections" id="26134"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Intra-abdominal Infections" id="13634"><Criterion>Subjects with Peritonitis</Criterion><SubCriteria><SubCriterion disease="Intra-abdominal Infections" id="13636">Subjects with secondary peritonitis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Intra-abdominal Infections" id="13647"><Criterion>Subjects with Co-morbid Conditions</Criterion></Inclusion><Inclusion disease="End stage renal disease" id="17648"><Criterion>Subjects with Dialysis Dependant Chronic Kidney Disease(DD-CKD)</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17652">Subjects with stage 5 CKD/end stage renal disease(ESRD)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="End stage renal disease" id="17682"><Criterion>Subjects with disease complications</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17686">Subjects with dialysis complications</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Intra-abdominal Infections" id="11257"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Intra-abdominal Infections" id="11259"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Intra-abdominal Infections" id="11267"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Intra-abdominal Infections" id="11272"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Intra-abdominal Infections" id="11276"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Intra-abdominal Infections" id="11277"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17515"><Criterion>Subjects with Renal Function Outside of Protocol Specified Limits</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17518"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17519"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17524"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17525">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17527"><Criterion>Subjects with Fluid/Electrolyte Imbalance</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17531"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17532">Subjects with peritonitis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17535"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="End stage renal disease" id="17536"><Criterion>Subjects with History of/Scheduled for Renal Replacement Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17537">Subjects with protocol specified dialysis related criteria</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17541"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="End stage renal disease" id="17542">Subjects with history of/scheduled for antidiabetics</SubCriterion><SubCriterion disease="End stage renal disease" id="17550">Subjects with history of/scheduled for antibiotics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="End stage renal disease" id="17553"><Criterion>Subjects with Contraindications to Study Procedure</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2011-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>13.94 Months</EnrollmentPeriod><EnrollmentRate>2.15 Patients/Month</EnrollmentRate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-06-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2016-02-17T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="13825"><TitleDisplay>Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)</TitleDisplay><TitleOfficial>A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study of the 12 Month Effect of Treatment With Once-Daily Triamcinolone Acetonide (Nasacort AQ Nasal Spray 110 microg) on the Growth Velocity of Children, 3 to 9 Years of Age, With Perennial Allergic Rhinitis (PAR)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">XRG5029C_3503</Identifier><Identifier type="NCT">NCT00449072</Identifier><Identifier type="Other">2014-004645-27</Identifier></Identifiers><Indications><Indication id="3201">Perennial allergic rhinitis</Indication></Indications><BiomarkerNames><BiomarkerName id="2534" role="Therapeutic effect marker" type="Biochemical">Hydrocortisone</BiomarkerName><BiomarkerName id="14220" role="Therapeutic effect marker" type="Biochemical">Cortisol/Creatinine ratio</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>loratadine</Name></Intervention><Intervention type="InterventionPrimary"><Name>triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Name><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="12937">triamcinolone acetonide (nasal spray, allergic rhinitis), Sanofi</Drug><IndicationsPioneer/><Companies><Company><Company id="1009547">Sanofi SA</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="12937" type="Drug"><TargetEntity id="91611" type="siDrug">Triamcinolone acetonide</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="3201" type="ciIndication"><TargetEntity id="D012221" type="MeSH"/><TargetEntity id="-1764444025" type="omicsDisease"/><TargetEntity id="299" type="siCondition"/></SourceEntity><SourceEntity id="3191" type="Action"><TargetEntity id="1738" type="Mechanism">Glucocorticoid Receptor (GR) Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1009547">Sanofi SA</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3191">Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="2954">Steroidal anti-inflammatory</Class></Class><Technologies><Technology id="615">Aerosol formulation dermatological</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="619">Nasal formulation local</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology></Technologies><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>299</PatientCountEnrollment><DateStart>2007-03-31T00:00:00Z</DateStart><DateEnd type="actual">2011-10-31T00:00:00Z</DateEnd><DateChangeLast>2018-06-23T05:38:05Z</DateChangeLast><DateAdded>2008-05-20T13:19:21Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Sanofi-Aventis</Affiliation><Name>Phyllis Diener</Name></Contact><Contact type="Scientific contact"><Affiliation>Sanofi-Aventis</Affiliation><Name>Akbar Akbary, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male participants (3 years to&amp;lt;/= 9 years + 0 days old) at visit 1 and no older than (9 years + 120 days) at visit 3; and, female participants (3 years to &amp;lt;/= 8 years + 0 days old) at visit 1 and no older than (8 years + 120 days) at visit 3: all sexually prepubertal (ie, Stage 1 of Tanner Classification of sexual maturity) at visit 1 and visit 3. A 5-day extension to the age upper bound would be permitted under certain circumstances to enable scheduling of visits 1 and 3&lt;/li&gt;&lt;li&gt;At least a one year history of PAR as assessed and documented by the investigator (with or without seasonal allergic rhinitis [SAR])&lt;/li&gt;&lt;li&gt;Positive skin test (prick or intradermal) to a perennial allergen that is present in the participant's environment. A skin test is considered positive if the wheal produced by the allergen is equal to or greater than that caused by positive control (histamine) or is at least 3 mm (prick test) or 7 mm (intradermal test) greater than the wheal of negative control (saline). If a skin test cannot be performed, the radioallergosorbent test (RAST) will be used as an alternative. Documented historical skin testing or RAST performed during the past year will be acceptable&lt;/li&gt;&lt;li&gt;Height within the third and 97th percentiles at screening (visit 1), visit 2, and at randomization (visit 3)&lt;/li&gt;&lt;li&gt;Symptomatic (daily AM instantaneous total nasal symptom score is &gt;/= 4 out of 12) on any 4 out of the last 7 consecutive days immediately prior to and including the morning of visit 3. Symptom ratings will be completed with the help of a parent/guardian/caregiver&lt;/li&gt;&lt;li&gt;Written informed consent and ability of parent or legal guardian of the participant to give a written informed consent before any study related procedures. Participants 7 years of age and older must provide a signed assent form&lt;/li&gt;&lt;li&gt;Participants must be toilet-trained&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Gross nasal anatomical deformities including large polyposis and marked deviated septum&lt;/li&gt;&lt;li&gt;History of or current cataract or glaucoma&lt;/li&gt;&lt;li&gt;History of hypersensitivity to the corticosteroids or to any excipient of the investigational product&lt;/li&gt;&lt;li&gt;Participant is the investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol&lt;/li&gt;&lt;li&gt;Height, weight, or body mass index (BMI)-for-age below the third or above the 97th percentile at visits 1, 2, or 3&lt;/li&gt;&lt;li&gt;Treatment with systemic corticosteroids (oral, intravenous, intramuscular, or intra-articular) within 3 months prior to visit 1&lt;/li&gt;&lt;li&gt;Treatment with systemic corticosteroids for &gt; 2 courses received up to one year before visit 1 is exclusionary. Up to two courses of systemic corticosteroids each course not exceeding 14 days up to one year before visit 1 was allowed&lt;/li&gt;&lt;li&gt;Treatment with inhaled, intranasal, or high potency topical corticosteroid exposure within 6 weeks prior to visit 1. Mild asthma will be well-controlled and without the use of inhaled corticosteroids within 6 weeks before screening (visit 1)&lt;/li&gt;&lt;li&gt;Immunotherapy, except stable (&gt;/= 1 month) maintenance schedule before visit 1&lt;/li&gt;&lt;li&gt;Treatment with any substance before visit 1 that may affect growth velocity and/or linear growth, such as, but not be limited to methylphenidate hydrochloride, thyroid hormone, growth hormone, anabolic steroids, calcitonin, estrogens, progestins, bisphosphonates, anticonvulsants, or phosphate-binding antacids&lt;/li&gt;&lt;li&gt;Treatment with any investigational product or device in the 30 days before visit 1 or at any time throughout the duration of this trial (visit 1 through visit 11)&lt;/li&gt;&lt;li&gt;Bone age as assessed by X-ray of the left hand and wrist that is outside +/- 1.5 years of participants chronological age at visit 2. Right hand and wrist will be radiographed in the event of bone injury to the left hand or wrist&lt;/li&gt;&lt;li&gt;Unresolved upper respiratory tract infection, sinus infection or nasal candidiasis (ie, symptomatic or under treatment)within the last 2 weeks before visit 3&lt;/li&gt;&lt;li&gt;Participants or parent/guardian/caregiver unable to demonstrate correct administration of the investigational product at visit 1&lt;/li&gt;&lt;li&gt;Concomitant disease other than PAR which could interfere with the study procedures or outcomes as determined by the investigator&lt;/li&gt;&lt;li&gt;History of hospitalization due to asthma within one year before screening (visit 1)&lt;/li&gt;&lt;li&gt;Abnormal 24 h urinary free cortisol level assessed at screening (visit 2)&lt;/li&gt;&lt;li&gt;The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Growth velocity: individual participant's growth velocity over double-blind treatment period was calculated using a linear regression of height over time. Height was measured on the same wall-mounted Harpenden stadiometer with the participant barefoot and in light clothing</Description><Timeframe>Day 1 to end of treatment (day 360)</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>A 24 h cortisol/creatinine ratio: urine cortisol and creatinine levels were determined at screening, at the end of treatment, and at follow-up visit using routine laboratory testing. The normal range for urinary free cortisol for 3- to 9-year-olds was considered to be (1.4 to 21 microg/24 h). No normal range is available for cortisol/creatinine ratio</Description><Timeframe>Baseline (2 to 6 weeks before day 1), end of treatment (day 360), and at follow-up (day 420)</Timeframe></Measure><Measure><Description>A 24 h urinary free cortisol levels: urine cortisol levels was determined at screening, at the end of treatment, and at follow-up visit using routine laboratory testing. The normal range for urinary free cortisol for 3- to 9-year-olds was considered to be (1.4 to 21 microg/24 h)</Description><Timeframe>Baseline (2 to 6 weeks before day 1), end of treatment (day 360), and at follow-up (day 420)</Timeframe></Measure><Measure><Description>Change from baseline in four individual nasal symptom scores at the end of treatment: PAR symptoms - nasal stuffiness, nasal discharge, sneezing, and nasal itching were scored upon arising in the morning according to the following four-point scale: 0 = symptom absent 1 = mild (present but not annoying to self) 2 = moderate (annoying to self but not interfering with sleep or daily living) 3 = severe (interfered with daily living and/or sleep) Individual symptom scores ranged from 0 (best outcome) to 3 (worst outcome). A negative value for change represents an improvement in symptoms</Description><Timeframe>For 7 days prior to randomization (baseline) and everyday for 7 days prior to day 360 (end of treatment)</Timeframe></Measure><Measure><Description>Change from baseline in instantaneous Total Nasal Symptom Score (TNSS): PAR symptoms - nasal stuffiness, nasal discharge, sneezing, and nasal itching were scored upon arising in the morning according to the following four-point scale: 0 = symptom absent 1 = mild (present but not annoying to self) 2 = moderate (annoying to self but not interfering with sleep or daily living) 3 = severe (interfered with daily living and/or sleep) TNSS was the sum of the individual symptom scores (ranging 0-3), and TNSS ranged from 0 (best outcome) to 12 (worst outcome). A negative value for change represents an improvement in symptoms</Description><Timeframe>For 7 days prior to randomization (baseline) and everyday for 7 days prior to day 360 (end of treatment)</Timeframe></Measure><Measure><Description>Global efficacy as assessed by the investigator during and at the end of the double-blind treatment period: global efficacy was assessed by the investigator using the following scale: 0 = no relief (symptoms unchanged or worse than before) 1 = slight relief (symptoms were present and only minimally improved) 2 = moderate relief (symptoms were present and could have been troublesome but were noticeably improved) 3 = marked relief (symptoms were greatly improved and although present were scarcely troublesome) 4 = complete relief (virtually no symptom present)</Description><Timeframe>Days 120, 240 and 360</Timeframe></Measure><Measure><Description>Global efficacy as assessed by the participant (with the help of a parent/guardian/caregiver) during and at the end of the double-blind treatment period: global efficacy was assessed by the participant (with the help of a parent/guardian/caregiver) using the following scale: 0 = no relief (symptoms unchanged or worse than before) 1 = slight relief (symptoms were present and only minimally improved) 2 = moderate relief (symptoms were present and could have been troublesome but were noticeably improved) 3 = marked relief (symptoms were greatly improved and although present were scarcely troublesome) 4 = complete relief (virtually no symptom present)</Description><Timeframe>Days 120, 240 and 360</Timeframe></Measure><Measure><Description>Number of participants with treatment-emergent adverse events (TEAE): adverse events that developed, worsened, or became serious during the double-blind treatment period or within 7 days after the last dose of double-blind investigational product (IP) are defined as TEAEs. A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose: Resulted in death Was life-threatening Required inpatient hospitalization or prolongation of existing hospitalization Resulted in persistent or significant disability/incapacity Was a congenital anomaly/birth defect Was a medically important event</Description><Timeframe>From day 1 to 7 days following end of treatment (day 360)</Timeframe></Measure><Measure><Description>Percentage of days participants used the rescue medication during the double-blind treatment phase of the study: children's claritin syrup was provided as a rescue medication to control allergic rhinitis (AR) symptoms and could be used throughout the study on an as needed basis. Use of rescue medication was to be documented in the participant's diary. The percentage of days that participants used the rescue medication during the double-blind treatment phase of the study</Description><Timeframe>Double-blind treatment period (days 1 to 360)</Timeframe></Measure><Measure><Description>Percentage of participants who used the rescue medication during the double-blind phase of the study: children's claritin syrup was provided as a rescue medication to control allergic rhinitis (AR) symptoms and could be used throughout the study on an as needed basis. Use of rescue medication was to be documented in the participant's diary. The percentage of participants who used the rescue medication during each of the study periods is reported</Description><Timeframe>Baseline (4 to 6 months before day 1), double-blind treatment period (days1 to 360) and follow-up (days 361 to 420)</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The primary objective of the study was to characterize the difference in prepubescent growth velocity in participants 3 to 9 years of age with perennial allergic rhinitis (PAR) treated with triamcinolone acetonide (TAA) nasal spray, (&lt;ulink linkType="Drug" linkID="12937"&gt;Nasacort AQ&lt;/ulink&gt; 110 microg in treatment group) or placebo (&lt;ulink linkType="Drug" linkID="12937"/&gt;Nasacort AQ placebo group) for 12 months.&lt;/para&gt;&lt;para&gt;The secondary objectives of this study were to compare the following in prepubertal participants treated with TAA nasal spray versus placebo: &lt;br/&gt;The 24-h urinary free cortisol levels and the cortisol/creatinine ratio (to measure the Hypothalamic-Pituitary Adrenal [HPA] axis function).&lt;br/&gt;The rate of treatment-emergent-adverse-events (TEAE).&lt;br/&gt;Global efficacy rated by the investigator and the participant separately.&lt;br/&gt;The rate of use of rescue medication during the study.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study would consist of two arms:&lt;br/&gt;&lt;ulink linkType="Drug" linkID="12937"/&gt;Arm I: participants  would receive TAA AQ (triamcinolone acetonide) 110 microg intranasally qd (one spray delivering 55 microg of TAA-AQ in each nostril) during the double-blind treatment period.   &lt;br/&gt;Arm II:  participants  would receive  TAA AQ placebo (one actuation/nostril) once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration.&lt;/para&gt;&lt;para&gt;All participants would be provided Children's &lt;ulink linkType="Drug" linkID="3516"&gt;Claritin&lt;/ulink&gt;  syrup (5 mg of loratadine per 5 ml)  as a rescue medication  for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Sanofi-Aventis Administrative Office</Name><Address1>Bridgewater</Address1><Address2>New Jersey</Address2><Address3>08807</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Allergic rhinitis</Disease><PatientSegments><PatientSegment><PatientSegment id="10202">Subjects with Perennial Allergic Rhinitis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10203">Subjects with Seasonal Allergic Rhinitis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00449072</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2014-004645-27</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Allergic rhinitis" id="14368"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Allergic rhinitis" id="14375">Assessment of impact of intervention on growth</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Allergic rhinitis" id="14351"><Endpoint>Assessment of use of Rescue Medication</Endpoint><SubEndpoints><SubEndpoint disease="Allergic rhinitis" id="14353">Frequency/rate of rescue medication use</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14356"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Allergic rhinitis" id="14362">Patient's global evaluation of allergic rhinitis</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14364"><Endpoint>Physician Global Assessment of Disease Activity</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14365"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Allergic rhinitis" id="14367">Assessment of serious/treatment emergent adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14368"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Allergic rhinitis" id="14369">Assessment of other efficacy parameters</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Allergic rhinitis" id="14385"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Allergic rhinitis" id="14397">Assessment of urinary analysis</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Allergic rhinitis" id="14503"><Criterion>Subjects with Perennial Allergic Rhinitis</Criterion></Inclusion><Inclusion disease="Allergic rhinitis" id="14506"><Criterion>Subjects with Seasonal Allergic Rhinitis(Hay Fever)</Criterion></Inclusion><Inclusion disease="Allergic rhinitis" id="14516"><Criterion>Patient Diagnosed with Allergic Rhinitis Based on Positive Skin Prick Test</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="14517">Subjects with wheal diameter &gt;/= 3 mm</SubCriterion><SubCriterion disease="Allergic rhinitis" id="14520">Subjects with positive histamine control</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Allergic rhinitis" id="14522"><Criterion>Patient Diagnosed with Allergic Rhinitis Based on Increased Serum Ig E Levels</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="14523">Patient diagnosed with allergic rhinitis based on RAST scores</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Allergic rhinitis" id="33762"><Criterion>Subjects with Protocol Specified Symptom Scales/Scores</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="14526">Subjects enrolled based on TNSS(Total nasal symptom score)</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Allergic rhinitis" id="11933"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11935">Subjects co-morbid with asthma</SubCriterion><SubCriterion disease="Allergic rhinitis" id="11936">Subjects with history of respiratory infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="11945"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Allergic rhinitis" id="11960"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Allergic rhinitis" id="11962">Subjects with history of/requiring immunotherapy</SubCriterion><SubCriterion disease="Allergic rhinitis" id="11963">Subjects with a history/current use of protocol prohibited corticosteroids</SubCriterion><SubCriterion disease="Allergic rhinitis" id="11966">Subjects with history of investigative product use</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Allergic rhinitis" id="11968"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2011-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>39.03 Months</EnrollmentPeriod><EnrollmentRate>7.66 Patients/Month</EnrollmentRate><DateFirstReceived>2007-03-15T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-05-20T13:19:21Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="168287"><TitleDisplay>Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)</TitleDisplay><TitleOfficial>Weekly Vinblastine for Chemotherapy Naive Children With Progressive Low Grade Glioma (PLGGs)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00575796</Identifier><Identifier type="Organisational Study">1000011227</Identifier></Identifiers><Indications><Indication id="1108">Glioma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>vinblastine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1079874" type="Company"><TargetEntity id="5038083002" type="organizationId">Pediatric Oncology Group of Ontario</TargetEntity></SourceEntity><SourceEntity id="16994" type="Company"><TargetEntity id="4298148028" type="organizationId">Hospital for Sick Children</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"/><TargetEntity id="D005910" type="MeSH"/><TargetEntity id="-1503483999" type="omicsDisease"/><TargetEntity id="680" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>17</NumberOfSites><CompaniesSponsor><Company id="16994">Hospital for Sick Children</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1079874">Pediatric Oncology Group of Ontario</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2007-10-31T00:00:00Z</DateStart><DateEnd type="estimated">2019-10-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-18T07:08:21Z</DateChangeLast><DateAdded>2014-01-23T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>IWK Health Centre</Affiliation><Name>Bruce Crooks, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>The Hospital for Sick Children, Toronto Canada</Affiliation><Name>Eric Bouffet, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must have been&amp;lt; 18 years of age when originally diagnosed&lt;/li&gt;&lt;li&gt;Histological diagnosis:&lt;ul&gt;&lt;li&gt;Patients must have histological verification of LGG at original diagnosis. Exceptions are optic pathway gliomas in children with neurofibromatosis or children with   large hypothalamic tumors for which a diagnostic biopsy does not seem necessary. Patients with disseminated low grade glioma are eligible&lt;ul&gt;&lt;li&gt;Astrocytoma variants: fibrillary, protoplasmic, gemistocytic, mixed&lt;/li&gt;&lt;li&gt;Pilocytic astrocytoma&lt;/li&gt;&lt;li&gt;Pleomorphic xanthoastrocytoma&lt;/li&gt;&lt;li&gt;Infantile desmoplastic astrocytoma&lt;/li&gt;&lt;li&gt;Ganglioglioma&lt;/li&gt;&lt;li&gt;Oligodendroglioma&lt;/li&gt;&lt;li&gt;Mixed glioma (including oligo-astrocytoma)&lt;/li&gt;&lt;li&gt;Pilomyxoid astrocytoma&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Performance Level:&lt;ul&gt;&lt;li&gt;Patients must have an ECOG performance status of 0, 1 or 2 or a Lansky/Karnofsky score&amp;gt; 50 &lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Life expectancy:&lt;ul&gt;&lt;li&gt;Patients must have a life expectancy of  2 months&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior therapy:&lt;ul&gt;&lt;li&gt;Patients are eligible at the time of diagnosis or first progression following treatment with surgery only&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Measurable disease:&lt;ul&gt;&lt;li&gt;Patients must have measurable disease, documented by radiographic criteria&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Concomitant medications&lt;ul&gt;&lt;li&gt;Steroids:&lt;ul&gt;&lt;li&gt;Steroids may be used at the time of inclusion to control progressive symptoms&lt;/li&gt;&lt;li&gt;Anti-epileptic medications are permitted - levetiracetam (Keppra) or clobazam (Frisium) being the preferred anti-epileptic medications for chronic use reserving phenytoin and lorazepam for acute seizure control&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Organ function requirements:&lt;ul&gt;&lt;li&gt;All patients must have adequate organ and bone marrow function within 7 days of starting chemotherapy (ANC = 1.0 x 10[9]/l, and platelet count = 100 x 10[9]/l [transfusion independent]). &lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Regulatory:&lt;ul&gt;&lt;li&gt;All patients and/or their parents or legal guardians must sign a written informed consent and all institutional requirements for human studies must be met. This study is open to all participants regardless of gender or ethnicity&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Inclusion criteria are restrictive. Patient must meet all inclusion criteria&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The response rate to weekly vinblastine</Description><Timeframe>70 Weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The correlation of biological features of LGG with tumor behavior</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>The progression-free survival with vinblastine</Description><Timeframe>At one, two and three years</Timeframe></Measure><Measure><Description>The quality of daily life during treatment</Description><Timeframe>26 Weeks</Timeframe></Measure><Measure><Description>To determine the role of telomere maintenance in the prognosis and evolution of PLGG</Description><Timeframe>Five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The overall objective of this study is to determine the efficacy of weekly vinblastine in      chemotherapy naive subjects with progressive or incompletely resected pediatric low grade      glioma, to generate estimates of the response rate, progression-free survival, toxicity and      quality of daily living among the population treated and determine biological factors which      will enable to predict tumor behaviour.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects  will be administered  with iv vinblastine sulfate  6 mg/m2 (10 mg maximum dose) once a week over a period of 26 weeks. MRI disease evaluation will be performed at weeks 12 and 26 (+/- 1 week). If response on MRI at week 26 &amp;gt; stable (ie, stable disease, objective or partial or complete response compared to the baseline MRI exam),  weekly inblastine will be continued to the total duration of treatment (ie,  70 weeks).  All subjects will be followed until they demonstrate clear signs tumor progression.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>Alberta Children's Hospital</Name><Address1>Calgary</Address1><Address2>Alberta</Address2><Address3>T3B 6A8</Address3><CountrySubDivision>Alberta</CountrySubDivision><Contacts/></Site><Site><Name>Allan Blair Cancer Centre</Name><Address1>Regina</Address1><Address2>Saskatchewan</Address2><Address3>S4T 7T1</Address3><CountrySubDivision>Saskatchewan</CountrySubDivision><Contacts/></Site><Site><Name>CancerCare Manitoba</Name><Address1>Winnipeg</Address1><Address2>Manitoba</Address2><Address3>R3E 0V9</Address3><CountrySubDivision>Manitoba</CountrySubDivision><Contacts/></Site><Site><Name>Centre Hospitalier Universitaire de Quebec</Name><Address1>Sainte-Foy</Address1><Address2>Quebec</Address2><Address3>G1V 4G2</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Centre Hospitalier Universitaire de Sherbrooke</Name><Address1>Sherbrooke</Address1><Address2>Quebec</Address2><Address3>J1H 5N4</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Children's Hospital of Eastern Ontario</Name><Address1>Ottawa</Address1><Address2>Ontario</Address2><Address3>K1H 8L1</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Children's Hospital of Western Ontario</Name><Address1>London</Address1><Address2>Ontario</Address2><Address3>N6C 2V5</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Children's and Women's Health Centre of British Columbia</Name><Address1>Vancouver</Address1><Address2>British Columbia</Address2><Address3>V6H 3V4</Address3><CountrySubDivision>British Columbia</CountrySubDivision><Contacts/></Site><Site><Name>Hospital Sainte-Justine</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><Address3>H3T 1C5</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>IWK Health Centre</Name><Address1>Halifax</Address1><Address2>Nova Scotia</Address2><Address3>B3K 6R8</Address3><CountrySubDivision>Nova Scotia</CountrySubDivision><Contacts/></Site><Site><Name>Janeway Child Health Centre</Name><Address1>St. John's</Address1><Address2>Newfoundland and Labrador</Address2><Address3>A1B 3V6</Address3><CountrySubDivision>Newfoundland and Labrador</CountrySubDivision><Contacts/></Site><Site><Name>Kingston General Hospital</Name><Address1>Kingston</Address1><Address2>Ontario</Address2><Address3>K7L 2V7</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>McMaster University</Name><Address1>Hamilton</Address1><Address2>Ontario</Address2><Address3>L8S 4J9</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Montreal Children's Hospital</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><Address3>H3H 1P3</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Saskatoon Cancer Center</Name><Address1>Saskatoon</Address1><Address2>Saskatchewan</Address2><Address3>S7N 4H4</Address3><CountrySubDivision>Saskatchewan</CountrySubDivision><Contacts/></Site><Site><Name>Stollery Children's Hospital</Name><Address1>Edmonton</Address1><Address2>Alberta</Address2><Address3>T6G 2J3</Address3><CountrySubDivision>Alberta</CountrySubDivision><Contacts/></Site><Site><Name>The Hospital for Sick Children</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M5G 1X8</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Central nervous system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9624">Subjects with Brain Tumors</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9632">Subjects with Gliomas</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9633">Subjects with Astrocytomas</PatientSegment><SubSegments><SubSegment id="9636">Subjects with diffuse astrocytoma (WHO Grade II)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9642">Subjects with Oligodendroglioma</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9644">Subjects with Mixed Gliomas</PatientSegment><SubSegments><SubSegment id="9645">Subjects with oligoastrocytoma (WHO Grade II)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9655">Subjects with Neuronal Tumors</PatientSegment><SubSegments><SubSegment id="9656">Subjects with ganglioglioma (WHO Grade I)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="9667">Subjects with Low Grade CNS Tumors</PatientSegment><SubSegments><SubSegment id="9668">Subjects with WHO grade I CNS tumors</SubSegment><SubSegment id="9669">Subjects with WHO grade II CNS tumors</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00575796</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Central nervous system tumor" id="13480"><Endpoint>Assessment of Response Rates (RR)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Central nervous system tumor" id="13477"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Central nervous system tumor" id="13472"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></OtherEndpoint><OtherEndpoint disease="Central nervous system tumor" id="13477"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></OtherEndpoint><OtherEndpoint disease="Central nervous system tumor" id="13478"><Endpoint>Assessment of Disease Progression</Endpoint></OtherEndpoint><OtherEndpoint disease="Central nervous system tumor" id="13480"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Central nervous system tumor" id="13483">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Central nervous system tumor" id="13484">Assessment of Complete Response</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Central nervous system tumor" id="13551"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Central nervous system tumor" id="13558">Assessment of hematological toxicity</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Central nervous system tumor" id="13567"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Central nervous system tumor" id="13568">Assessment of treatment-related mortality</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Central nervous system tumor" id="12981"><Criterion>Subjects with Brain Tumors</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="12989"><Criterion>Subjects with Gliomas</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="12990"><Criterion>Subjects with Astrocytomas</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="12993">Subjects with diffuse astrocytoma (WHO Grade II)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="12999"><Criterion>Subjects with Oligodendroglioma</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13001"><Criterion>Subjects with Mixed Gliomas</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13002">Subjects with Oligoastrocytoma (WHO Grade II)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13012"><Criterion>Subjects with Neuronal Tumors</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13013">Subjects with ganglioglioma (WHO Grade I)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13027"><Criterion>Subjects with Low Grade CNS Tumors</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13028">Subjects with WHO grade I CNS tumors</SubCriterion><SubCriterion disease="Central nervous system tumor" id="13029">Subjects with WHO grade II CNS tumors</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13033"><Criterion>Subjects with Measurable Disease</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13036"><Criterion>Subjects co-morbid with malignancy/tumor</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13038"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13042">Subjects with life expectancy of four months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13045"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13052">Subjects with Karnofsky score of 50 or higher</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Central nervous system tumor" id="13062"><Criterion>Subjects with History of Use of Non-chemotherapeutic Drugs</Criterion></Inclusion><Inclusion disease="Central nervous system tumor" id="13065"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Central nervous system tumor" id="13066">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2018-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>64.03 Months</EnrollmentPeriod><EnrollmentRate>0.78 Patients/Month</EnrollmentRate><DateFirstReceived>2007-12-14T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="183666"><TitleDisplay>A Pilot Study of Early Postpartum Intrauterine Contraception</TitleDisplay><TitleOfficial>A Pilot Study of Early Postpartum Intrauterine Contraception</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00997932</Identifier><Identifier type="Organisational Study">SFP3-14</Identifier><Identifier type="Trial Acronym">ImmPPIUD</Identifier></Identifiers><Indications><Indication id="1778">Female contraception</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>levonorgestrel (intrauterine system), Bayer Schering</Name><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="14885">levonorgestrel (intrauterine system), Bayer Schering</Drug><IndicationsPioneer/><Companies><Company><Company id="20634">University of North Carolina</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="20634" type="Company"><TargetEntity id="4298218909" type="organizationId">University of North Carolina</TargetEntity></SourceEntity><SourceEntity id="1778" type="ciIndication"><TargetEntity id="541" type="siCondition"/></SourceEntity><SourceEntity id="624" type="Action"><TargetEntity id="559" type="Mechanism">Progesterone Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="20634">University of North Carolina</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="624">Progesterone receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="70">Anticonvulsant agent</Class><Class id="7251">Female contraceptive</Class></Class><Technologies><Technology id="560">Drug implant</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="630">Stereochemistry</Technology><Technology id="90">Steroid</Technology><Technology id="623">Vaginal formulation</Technology></Technologies><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Prevention</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2009-06-30T00:00:00Z</DateStart><DateEnd type="actual">2012-11-30T00:00:00Z</DateEnd><DateChangeLast>2017-04-04T05:04:53Z</DateChangeLast><DateAdded>2014-04-28T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>University of North Carolina, Chapel Hill</Affiliation><Email>gstuart@med.unc.edu</Email><Name>Gretchen Stuart, MD, MPHTM</Name><Phone>919-843-9546</Phone></Contact><Contact type="Public contact"><Email>amy_bryant@med.unc.edu</Email><Name>Amy Bryant</Name><Phone>919-843-9546</Phone></Contact><Contact type="Public contact"><Affiliation>University of North Carolina at Chapel Hill; Chapel Hill; North Carolina; 27514; United States</Affiliation><Name>Stuart</Name><Phone>919-843-9546</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Currently pregnant with a single gestation of at least 27 completed weeks estimated gestational age, with no complications of pregnancy including, but not limited to, pre-eclampsia, non-gestational diabetes, anemia&lt;/li&gt;&lt;li&gt;Desires to use intrauterine contraception (IUD) after delivery&lt;/li&gt;&lt;li&gt;Anticipates having a vaginal delivery&lt;/li&gt;&lt;li&gt;No intention to leave the area 7 months after enrollment&lt;/li&gt;&lt;li&gt;Able to consent to participate in the study in English&lt;/li&gt;&lt;li&gt;Has no known uterine anomalies&lt;/li&gt;&lt;li&gt;Has no allergies to any components of the intrauterine contraception&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Prior cesarean delivery&lt;/li&gt;&lt;li&gt;Having been treated for pelvic inflammatory disease within 3 months prior to the start of the pregnancy&lt;/li&gt;&lt;li&gt;Allergic to betadine&lt;/li&gt;&lt;li&gt;Allergy to lidocaine&lt;/li&gt;&lt;li&gt;Medical or personal conditions which in the judgment of study staff contradict participation in the study&lt;/li&gt;&lt;li&gt;Any contraindications to use of the levonorgestrel-releasing intrauterine contraceptive system (&lt;ulink linkType="Drug" linkID="14885"&gt;Mirena&lt;/ulink&gt;) which includes: known or suspected breast carcinoma, acute liver disease or liver tumor, history of ectopic pregnancy, cervical cancer or carcinoma in situ&lt;/li&gt;&lt;li&gt;After enrollment, and after delivery of the infant but before IUD insertion subjects will be excluded by checking with the attending obstetric physician and/or obstetric medical chart for the following:&lt;ul&gt;&lt;li&gt;Endometritis or chorioamnionitis during the intrapartum period&lt;/li&gt;&lt;li&gt;Membranes ruptured for &gt; 24 h prior to delivery&lt;/li&gt;&lt;li&gt;Fever &gt;/= 38degC&lt;/li&gt;&lt;li&gt;The need to use additional medications other than pitocin and/or misoprostol to control postpartum bleeding&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>IUD expulsion: expulsion of the LNG-IUS</Description><Timeframe>From time of insertion to final study date which is 6 months after IUD insertion</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study was to measure intrauterine device (IUD) expulsion and the      feasibility of conducting a future clinical trial to evaluate placement of the      levonorgestrel-releasing intrauterine contraceptive (&lt;ulink linkType="Drug" linkID="14885"&gt;Mirena&lt;/ulink&gt;) 10 min to 48 h postpartum.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This was a single arm cohort study of women who desired to receive a levonorgestrel releasing intrauterine system (LNG-IUS) (52 mg, five year duration postpartum placement of LNG-IUS within 10 min to  48 h) within 48 h of uncomplicated vaginal delivery. The complete cohort of all women enrolled and stated they wanted an LNG-IUS between 48 and 72 h of vaginal delivery. Women would be enrolled during a prenatal care visit when they reported they desired to use the LNG-IUS after the birth of their infant . A 6-month follow-up would entail three follow-up visits; 4 to 6 weeks, 3 and 6 months.&lt;br/&gt;A 40  women stated enrolled in the study prior to labor, and baseline data were obtained. After delivery 29 women remained both interested in the study and would still be eligible to receive the LNG-IUS prior to discharge from the hospital.&lt;br/&gt;Of the 29 women who received the LNG-IUS prior to discharge from the hospital 11 women had an LNG-IUS expulsion prior to 6 months postpartum.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of North Carolina at Chapel Hill</Name><Address1>Chapel Hill</Address1><Address2>North Carolina</Address2><Address3>27514</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>The University of North Carolina at Chapel Hill</Name><Address1>Chapel Hill</Address1><Address2>North Carolina</Address2><Address3> 27514</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Contraception</Disease><PatientSegments><PatientSegment><PatientSegment id="8700">Subjects Willing Postpartum Contraception</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00997932</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Contraception" id="13317"><Endpoint>Contraceptive Failure Assessment</Endpoint><SubEndpoints><SubEndpoint disease="Contraception" id="13319">Expulsion/removal</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Contraception" id="13331"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Contraception" id="13333">Acceptability/satisfaction</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Contraception" id="45984"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Contraception" id="13336">Accessibility/Feasibility Assessment</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Contraception" id="7287"><Criterion>Subjects Willing Postpartum Contraception</Criterion></Inclusion><Inclusion disease="Contraception" id="7292"><Criterion>Subjects Willing Non-hormonal Contraception</Criterion><SubCriteria><SubCriterion disease="Contraception" id="7294">Subjects willing intrauterine device(IUD)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Contraception" id="7303"><Criterion>Subjects without Contraindication to Contraception</Criterion></Inclusion><Inclusion disease="Pregnancy Induced Hypertension" id="21159"><Criterion>Pregnancy Related Other Inclusions</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="21160">Pregnant women in general health</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="21175">Subjects with singleton pregnancy</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="21177">Subjects with contraception</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="21183">Women with term delivery</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Contraception" id="15917"><Criterion>Subjects with History of Ectopic Pregnancy</Criterion></Exclusion><Exclusion disease="Contraception" id="15920"><Criterion>Subjects with Contraindication to Contraception</Criterion><SubCriteria><SubCriterion disease="Contraception" id="15922">Subjects with allergy/hypersensitivity</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Contraception" id="15924"><Criterion>Subjects co-morbid with genitourinary disorders</Criterion></Exclusion><Exclusion disease="Contraception" id="15929"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Contraception" id="15933"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Contraception" id="15934"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Contraception" id="15935"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Contraception" id="15936"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18753"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18759">Subjects with planned/history of anti-inflammatory drugs</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="18775">Use of protocol specified other medications/products</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18776"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18791">Hypersensitivity/contraindication to other medications/therapy</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="18793">Hypersensitivity/Contraindications to study medications or its excipients</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18794"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18802">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="18805">Subjects co-morbid with inflammatory disease</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="18809">Subjects with neoplasia/malignancy</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="18814">Subjects with urogenital disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18819"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18821">Subjects with planned/history of pregnancy related surgery</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pregnancy Induced Hypertension" id="18849"><Criterion>Exclusion based on Pregnancy</Criterion><SubCriteria><SubCriterion disease="Pregnancy Induced Hypertension" id="18852">Fetal disorders</SubCriterion><SubCriterion disease="Pregnancy Induced Hypertension" id="18860">Subjects with maternal diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Contraception" id="26923"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Contraception" id="15915">Subjects who are Pregnant/Planning Pregnancy</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-10-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2010-08-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>14.06 Months</EnrollmentPeriod><EnrollmentRate>2.84 Patients/Month</EnrollmentRate><DateFirstReceived>2009-09-28T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-04-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="219873"><TitleDisplay>A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis</TitleDisplay><TitleOfficial>A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Effect on Sweat Production of Three Concentrations of Topically Applied BBI-4000 in Subjects With Axillary Hyperhidrosis</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02336503</Identifier><Identifier type="Organisational Study">BBI-4000-CL-201</Identifier></Identifiers><Indications><Indication id="2225">Hyperhidrosis</Indication></Indications><BiomarkerNames><BiomarkerName id="44975" role="Therapeutic effect marker" type="Physiological">Sweat rate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sofpironium bromide</Name><Drug id="82650">sofpironium bromide</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="82650">sofpironium bromide</Drug><IndicationsPioneer/><Companies><Company><Company id="1068179">Brickell Biotech Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1068179" type="Company"><TargetEntity id="5000815902" type="organizationId">Brickell Biotech Inc</TargetEntity></SourceEntity><SourceEntity id="2225" type="ciIndication"><TargetEntity id="R61" type="ICD10"/><TargetEntity id="10020642" type="MEDDRA"/><TargetEntity id="D006945" type="MeSH"/><TargetEntity id="-982941024" type="omicsDisease"/><TargetEntity id="1230" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2b Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>12</NumberOfSites><CompaniesSponsor><Company id="1068179">Brickell Biotech Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="162">Acetylcholine receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1880">Dermatological agent</Class></Class><Technologies><Technology id="611">Dermatological formulation</Technology><Technology id="775">Dermatological gel formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>189</PatientCountEnrollment><PatientCountEvaluable>189</PatientCountEvaluable><DateStart>2015-02-28T00:00:00Z</DateStart><DateEnd type="actual">2015-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T00:30:15Z</DateChangeLast><DateAdded>2015-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Brickell Biotech, Inc.</Affiliation><Name>Elizabeth Hussey, Pharm.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Primary axillary hyperhidrosis of at least 6 months duration&lt;/li&gt;&lt;li&gt;Hyperhidrosis disease severity score of 3 or 4 at baseline&lt;/li&gt;&lt;li&gt;Gravimetric test at baseline indicating at least 50 mg of sweat production at rest in each axilla, in 5 min (room temperature)&lt;/li&gt;&lt;li&gt;Willing to refrain from using any other antiperspirant agent for the duration of the study&lt;/li&gt;&lt;li&gt;Females of childbearing potential must agree to use a medically acceptable method of contraception while participating in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any skin or subcutaneous tissue conditions in the axilla or near the axillary area, other than hyperhidrosis&lt;/li&gt;&lt;li&gt;Prior use of any prohibited medication(s) or procedure(s) within the specified timeframe, including:&lt;ul&gt;&lt;li&gt;Botulinum toxin to the axillary area within one year of the baseline visit&lt;/li&gt;&lt;li&gt;Axillary iontophoresis within 12 weeks of baseline visit&lt;/li&gt;&lt;li&gt;Axillary thermolysis, sympathectomy or surgical procedures of the axillary area at any time in the past&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Use of systemic and/or topical anticholinergic treatment within 30 days of the baseline visit&lt;/li&gt;&lt;li&gt;Patients with hyperhidrosis symptoms initiated or exacerbated with their menopause&lt;/li&gt;&lt;li&gt;Patients with history of diabetes mellitus, renal impairment, hepatic impairment, thyroid disease, malignancy, glaucoma, intestinal obstructive or motility disease, obstructive uropathy, myasthenia gravis, benign prostatic hyperplasia (BPH), neurological conditions, psychiatric conditions, Sjogren's syndrome, Sicca syndrome, or cardiac abnormalities that may alter normal sweat production or may be exacerbated by the use of anticholinergics&lt;/li&gt;&lt;li&gt;Patients with known hypersensitivity to glycopyrrolate, anticholinergics, or any of the components of the topical formulation&lt;/li&gt;&lt;li&gt;Pregnant or lactating women&lt;/li&gt;&lt;li&gt;Use of an investigational drug within 30 days prior to the baseline visit&lt;/li&gt;&lt;li&gt;Prior treatment with the study drug in a previous trial&lt;/li&gt;&lt;li&gt;Any major illness within 30 days before the screening examination&lt;/li&gt;&lt;li&gt;Any other condition or laboratory abnormality that, in the judgment of the investigator, would put the patient at unacceptable risk for participation in the study or may interfere with the assessments included in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Proportion of patients achieving at least two-point improvement in HDSS</Description><Timeframe>From baseline to week 4</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Hyperhidrosis Disease Severity Measure Axillary (HDSM-Ax) measure</Description></Measure><Measure><Description>Quality of life</Description></Measure><Measure><Description>Absolute change in gravimetrically measured sweat production</Description><Timeframe>From baseline to week 4</Timeframe></Measure><Measure><Description>Percent change in gravimetrically measured sweat production</Description><Timeframe>From baseline to week 4</Timeframe></Measure><Measure><Description>Proportion of patients achieving at least one-point improvement in HDSS</Description><Timeframe>From baseline to week 4</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In December 2015, results were presented. Consistent with previous results, at all three concentrations, BBI-4000 was well-tolerated   [&lt;ulink linkType="Reference" linkID="1722315"&gt;1722315&lt;/ulink&gt;]. Similar results were presented in March 2016 [&lt;ulink linkType="Reference" linkID="1740963"&gt;1740963&lt;/ulink&gt;]. In October 2017, similar positive results were presented [&lt;ulink linkType="Reference" linkID="1974069"&gt;1974069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, further results were presented. Throughout the study, the incidence of local tolerability signs was low (&amp;lt; 10%) and were predominantly mild to moderate in severity and resolved spontaneously. Mild and transient treatment-related anticholinergic side effects were predominant and occurred in 16 study patients randomized to BBI-4000 [&lt;ulink linkType="Reference" linkID="1740963"&gt;1740963&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1741871"&gt;1741871&lt;/ulink&gt;]. In October 2017, similar positive results were presented [&lt;ulink linkType="Reference" linkID="1974069"&gt;1974069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2017, further  positive results were presented. Treatment-related serious adverse events were not reported. Treatment Emergent Adverse Events (TEAEs) were reversible when treatment was discontinued    [&lt;ulink linkType="Reference" linkID="1974069"&gt;1974069&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this phase IIb, multicenter, randomized, double-blind, vehicle-controlled study was to evaluate the safety and efficacy of three concentrations of topically applied &lt;ulink linkType="Drug" linkID="82650"&gt;BBI-4000&lt;/ulink&gt; and  vehicle when applied once a day for 4 weeks, for the treatment of axillary hyperhidrosis [&lt;ulink linkType="Reference" linkID="1630977"&gt;1630977&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1722315"&gt;1722315&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1974069"&gt;1974069&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2015, results were presented. Primary endpoint (statistically significant and clinically meaningful 2-grade improvement in the Hyperhidrosis Disease Severity Score [HDSS] in a dose-related fashion) was achieved in this study. Similarly, in the  Hyperhidrosis Disease Severity Measure Axillary (HDSM-Ax) patient reported outcome measure, BBI-4000 ahs shown statistically significant and clinically meaningful 1- and 2-grade improvement.  [&lt;ulink linkType="Reference" linkID="1722315"&gt;1722315&lt;/ulink&gt;]. Similar results were presented  in March 2016 [&lt;ulink linkType="Reference" linkID="1740963"&gt;1740963&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, further results were presented.  Patients (38.3%)  improved in &amp;gt; 2 points  at the maximum dose (15%) on HDSS at day 29 versus 12.2% with vehicle (p &amp;lt; 0.01). A statistically significant 1- and 2-grade improvement was achieved by BBI-4000 in a newly developed patient reported outcome measure, the Hyperhidrosis Disease Severity Measure Axillary (HDSM-Ax). In the 15% treatment group versus 19.5% for vehicle, 44.7% achieved a greater than 2-point improvement at day 29 (p = 0.01), while  in the 15% treatment group versus 43.9% vehicle, 72.3% achieved a greater than 1-point improvement (p = 0.01). A trend in reduction of gravimetrically measured sweat production was observed in the BBI-4000 15% treatment group versus vehicle. A statistically significant improvement was in  observed 48.9% of patients in the 15% group in a composite measure (ITT analysis) of patients who achieved at least a 1-grade improvement in their HDSM-Ax and a 50% reduction in gravimetric sweat production compared to 26.8% of vehicle-treated patients (p = 0.03). An improvement in the patients' quality of life was also demonstrated in the BBI-4000 15% treatment group. This quality of life was  measured by the Daily Quality of Life Index (DLQI) modified for sweating [&lt;ulink linkType="Reference" linkID="1740963"&gt;1740963&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, results were presented. At day 29, increase of &gt;/= 2-points on HDSS was shown by 39.5 and 8.6% (p &amp;lt; 0.01) of patients in the treatment (maximum dose) and vehicle group, respectively. For HDSM-Ax, &gt;/= 2-point improvement was shown by 42.1 and 14.3% (p = 0.01); and &gt;/= 1-point improvement by 71.1 and 37.1% (p = 0.01) of patients treated with maximum dose of BBI-4000 and vehicle, respectively. Mean change in gravimetrically measured sweat production for BBI-4000 and for vehicle was 219.2, and 139.1 mg/5 min, respectively at day 29 [&lt;ulink linkType="Reference" linkID="1741871"&gt;1741871&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2017, positive results were presented. All three doses of BBI-4000  met the primary efficacy endpoints by successfully achieving statistical significance compared to vehicle for the HDSM-Ax. BBI-4000 demonstrated statistical significance for change in HDSM-Ax from baseline to end of therapy (EOT) as a continuous measure in all dose groups versus vehicle (p &amp;lt; 0.0001). Statistical significance for the proportion of subjects who achieved at least a one-grade improvement in HDSM-Ax from baseline to EOT in all dose groups versus vehicle (p &amp;lt; 0.001). BBI-4000 demonstrated statistical significance for the proportion of patients who achieved at least a two-grade improvement in HDSM-Ax from baseline to EOT in all dose group versus vehicle (p &amp;lt; 0.001). Statistical significance for change from baseline to EOT in gravimetric sweat production ('GSP') in 5 and 15% dose groups versus vehicle (p &amp;lt; 0.002). Statistical significance for the proportion of patients achieving at least a 50% reduction in GSP from baseline to EOT in 5 and 15% dose groups versus vehicle (p &amp;lt; 0.02). Statistical significance for composite responder analysis, where an individual subject must have had a 50% reduction in GSP combined with a one or two-grade improvement in HDSM-Ax measure from baseline to EOT in all dose groups versus vehicle (p &amp;lt; 0.0006  and p&amp;lt;0.002 for one- and  two-grade improvement, respectively). Statistical significance for one and two-grade improvements in the Hyperhidrosis Disease Severity Scale (HDSS) from baseline to EOT in all dose groups versus vehicle (p &amp;lt; 0.05   and p &amp;lt; 0.005 for one- and  two-grade improvement, respectively). Statistical significance for the Dermatology Life Quality Index (DLQI) score from baseline to EOT in all dose groups versus vehicle (p &amp;lt; 0.004)                           [&lt;ulink linkType="Reference" linkID="1974069"&gt;1974069&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomized to receive either &lt;ulink linkType="Drug" linkID="82650"&gt;BBI-4000&lt;/ulink&gt; (low-, middle- or high-concentrations) or placebo, applied &lt;ulink linkType="Drug" linkID="82650"/&gt;once a day for 4 weeks in their axilla. The 4-week treatment period would be followed by a 2-week follow-up period.&lt;/para&gt;&lt;para&gt;Safety would be assessed through collection of vital signs, adverse events, local skin      responses, hematology and serum chemistry laboratory testing and ECGs. Efficacy would be assessed using the Hyperhidrosis Disease Severity Scale (patient reported      outcome) and through gravimetrically measured sweat production. Pharmacokinetic blood samples would be taken from study patients from selected centers.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to apply either 5, 10 or 15% of BBI-4000 or placebo gel to their underarms once-daily  for 28 days [&lt;ulink linkType="Reference" linkID="1722315"&gt;1722315&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1740963"&gt;1740963&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1741871"&gt;1741871&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1974069"&gt;1974069&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Academic Dermatology Associates</Name><Address1>Albuquerque</Address1><Address2>New Mexico</Address2><Address3>87106</Address3><CountrySubDivision code="NM">New Mexico</CountrySubDivision><Contacts/></Site><Site><Name>Center for Clinical and Cosmetic Research</Name><Address1>Aventura</Address1><Address2>Florida</Address2><Address3>33180</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Center for Dermatology Clinical Research, Inc.</Name><Address1>Fremont</Address1><Address2>California</Address2><Address3>94538</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>International Clinical Research</Name><Address1>Sanford</Address1><Address2>Florida</Address2><Address3>32771</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>International Dermatology Research, Inc.</Name><Address1>Miami</Address1><Address2>Florida</Address2><Address3>33144</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Minnesota Clinical Study Center</Name><Address1>Fridley</Address1><Address2>Minnesota</Address2><Address3>55432</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>Saint Louis University Dermatology</Name><Address1>Saint Louis</Address1><Address2>Missouri</Address2><Address3>63122</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>Shideler Clinical Research Center</Name><Address1>Carmel</Address1><Address2>Indiana</Address2><Address3>46032</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>The Center for Skin Research</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77056</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>The Indiana Clinical Trials Center</Name><Address1>Plainfield</Address1><Address2>Indiana</Address2><Address3>46168</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Therapeutics Clinical Research</Name><Address1>San Diego</Address1><Address2>California</Address2><Address3>92123</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Virginia Clinical Research, Inc.</Name><Address1>Norfolk</Address1><Address2>Virginia</Address2><Address3>23507</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other dermatological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17864">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16008">Subjects with Hyperhidrosis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02336503</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other dermatological disease" id="43234"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other dermatological disease" id="43522">Assessment by Hyperhidrosis Disease Severity Scale (HDSS)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other dermatological disease" id="43231"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Other dermatological disease" id="43520">Gravimetric measurement of sweat production</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other dermatological disease" id="43234"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other dermatological disease" id="43522">Assessment by Hyperhidrosis Disease Severity Scale (HDSS)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other dermatological disease" id="42862"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint><OtherEndpoint disease="Other dermatological disease" id="43232"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other dermatological disease" id="32830"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other dermatological disease" id="33233"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="33235">Subjects with hyperhidrosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other dermatological disease" id="34480"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other dermatological disease" id="24365"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Other dermatological disease" id="24589"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other dermatological disease" id="24956"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24367">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="25143"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24762">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="25604"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24356">Subjects previously participated/or currently participating in an investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="25849"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion></Exclusion><Exclusion disease="Other dermatological disease" id="26749"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Other dermatological disease" id="27632"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Other dermatological disease" id="29140"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2015-10-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>8.13 Months</EnrollmentPeriod><EnrollmentRate>23.25 Patients/Month</EnrollmentRate><DateFirstReceived>2015-01-08T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-10-28T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-12-22T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2015-12-22T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="293247"><TitleDisplay>Ketamine on pain reduction after PCNL surgery</TitleDisplay><TitleOfficial>Evaluation of effect of ketamine administration on pain reduction after PCNL surgery</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT201510083773N16</Identifier><Identifier type="Secondary Organisational">IR.TUMS.1394.1134</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames><BiomarkerName id="1905" role="Therapeutic effect marker" type="Physiological">Peak expiratory flow rate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ketamine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1043016" type="Company"><TargetEntity id="5035525669" type="organizationId">Tehran University of Medical Sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043016">Tehran University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Surgical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>66</PatientCountEnrollment><PatientCountEvaluable>66</PatientCountEvaluable><DateStart>2014-12-09T00:00:00Z</DateStart><DateChangeLast>2017-11-14T07:10:36Z</DateChangeLast><DateAdded>2017-04-18T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tehran University Of Medical Science</Affiliation><Email>Golnar_shayanpour@yahoo.com</Email><Name>Dr.Golnar Shyanpour</Name><Phone>00982163120 00989336891769</Phone></Contact><Contact type="Scientific contact"><Affiliation>Tehran University of Medical Sciences</Affiliation><Email>Golnar_shayanpour@yahoo.com</Email><Name>Dr.Golnar Shayanpour</Name><Phone>00982163120 00989336891769</Phone></Contact><Contact type="Public contact"><Affiliation>Tehran University Of Medical Science</Affiliation><Email>Golnar_shyanpour@yahoo.com</Email><Name>Dr.Golnar Shayanpour</Name><Phone>00982163120 00989336891769</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Paitent undergoing PCNL surgery in Sina hospital&lt;/li&gt;&lt;li&gt;Age 18 to 70&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Addiction&lt;/li&gt;&lt;li&gt;History of mental illness and high blood pressure&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pain after surgery: postoperative pain score evaluated using visual analog scale (VAS)</Description><Timeframe>4 to 6 h after surgery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Sedation scores</Description></Measure><Measure><Description>Time to first rescue analgesia</Description></Measure><Measure><Description>Rescue analgesic requirement</Description></Measure><Measure><Description>Peak expiratory flow rate (PEF)</Description></Measure><Measure><Description>Hemodynamic parameters</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim was to study the effect of local ketamine use in percutaneous nephrolitotomy surgery on post-operation pain reduction and total analgesic consumption. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In March 2017, results were published. In the intervention group, the mean VAS scores were significantly lower  compared with the control group at the recovery, and 4 and 6 h postoperatively (p = 0.001). Significantly lower  mean time to first rescue analgesia in the postoperative period was  observed in the control group (64.5 +/-  8.1 min) compared with the intervention group (122 +/- 18.4 min). In the ketamine group, the trend of first opioid administration was significantly lower  (p &amp;lt; 0.009). Significant differences in PEF was not observed between the two groups in the postoperative period (p = 0.622)[&lt;ulink linkType="Reference" linkID="1981406"&gt;1981406&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients (n = 66) would receive either ketamine 1.5 mg/kg at the end of surgery through the nephrostomy tube to renal capsule and under skin  or no  intervention. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were randomized to two groups with 33 patients in each group. In group K (ketamine), 20 ml saline solution containing 1.5 mg/kg ketamine was infiltrated into the nephrostomy tract and in group C (control) , 20 ml saline solution was infiltrated into the nephrostomy tract at the end of surgery [&lt;ulink linkType="Reference" linkID="1981406"&gt;1981406&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="688179">ketamine</Intervention><Treatments><Treatment><Dose>1.5 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Sina Hospital</Name><Address1>Tehran</Address1><Address2>Tehran</Address2><CountrySubDivision>Tehran</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Dr.Golnar Shayanpour</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8424">Subjects with Post-Operative Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT201510083773N16</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="34860">Assessment of Pain by Visual Analog Scale (VAS)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22142"><Criterion>Subjects with Peri-operative Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22143">Subjects with post operative pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20095"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="20097">Subjects with pre-specified vital signs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20102"><Criterion>Subjects with pre-specified neuropsychological assessments</Criterion></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2015-12-20T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>12.39 Months</EnrollmentPeriod><EnrollmentRate>5.33 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-04-18T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-11-15T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="29331"><TitleDisplay>Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor</TitleDisplay><TitleOfficial>A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/day or Octreotide Depot and Placebo</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Other">2006-004507-18</Identifier><Identifier type="NCT">NCT00412061</Identifier><Identifier type="Organisational Study">CRAD001C2325</Identifier><Identifier type="Trial Acronym">RADIANT-2</Identifier></Identifiers><Indications><Indication id="1128">Neuroendocrine tumor</Indication><Indication id="2538">Carcinoid tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="57" role="Therapeutic effect marker" type="Genomic;Proteomic">Chromogranin-A</BiomarkerName><BiomarkerName id="1550" role="Therapeutic effect marker" type="Biochemical">Hydroxyindoleacetic Acid</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>octreotide acetate (long-acting formulation), Novartis</Name><Drug id="3735">octreotide acetate (long-acting formulation), Novartis</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>everolimus</Name><Drug id="13340">everolimus</Drug></Intervention><Intervention type="InterventionPrimary"><Name>everolimus + octreotide</Name></Intervention><Intervention type="InterventionPrimary"><Name>everolimus + octreotide LAR (double-blind)</Name></Intervention><Intervention type="InterventionPrimary"><Name>everolimus + octreotide LAR (open-label)</Name></Intervention><Intervention type="InterventionPrimary"><Name>octreotide acetate (long-acting formulation), Novartis</Name><Drug id="3735">octreotide acetate (long-acting formulation), Novartis</Drug></Intervention><Intervention type="InterventionPrimary"><Name>placebo + octreotide</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="13340">everolimus</Drug><IndicationsPioneer><Indication id="2538">Carcinoid tumor</Indication></IndicationsPioneer><Companies><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3735">octreotide acetate (long-acting formulation), Novartis</Drug><IndicationsPioneer><Indication id="2538">Carcinoid tumor</Indication></IndicationsPioneer><Companies><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3735">octreotide acetate (long-acting formulation), Novartis</Drug><IndicationsPioneer><Indication id="2538">Carcinoid tumor</Indication></IndicationsPioneer><Companies><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3735" type="Drug"><TargetEntity id="120090" type="siDrug">Octreotide acetate</TargetEntity><TargetEntity id="120090" type="siDrug">Octreotide acetate</TargetEntity></SourceEntity><SourceEntity id="13340" type="Drug"><TargetEntity id="210424" type="siDrug">Everolimus</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="1128" type="ciIndication"><TargetEntity id="C7A" type="ICD10"/><TargetEntity id="209" type="ICD9"/><TargetEntity id="10052399" type="MEDDRA"/><TargetEntity id="D018358" type="MeSH"/><TargetEntity id="-1333045072" type="omicsDisease"/><TargetEntity id="1422" type="siCondition"/></SourceEntity><SourceEntity id="2538" type="ciIndication"><TargetEntity id="C7A.0" type="ICD10"/><TargetEntity id="10007275" type="MEDDRA"/><TargetEntity id="D002276" type="MeSH"/><TargetEntity id="-670291637" type="omicsDisease"/><TargetEntity id="662" type="siCondition"/></SourceEntity><SourceEntity id="10240" type="Action"><TargetEntity id="1705" type="Mechanism">Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1120" type="Action"><TargetEntity id="306" type="Mechanism">Somatostatin Agonists</TargetEntity></SourceEntity><SourceEntity id="76090" type="Action"><TargetEntity id="3739" type="Mechanism">mTOR Complex 1 (mTORC1) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>125</NumberOfSites><CompaniesSponsor><Company id="23137">Novartis AG</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="10240">mTOR inhibitor</Action><Action id="1120">Somatostatin receptor agonist</Action><Action id="76090">mTOR complex 1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="2970">Anti-emetic</Class><Class id="3272">Growth hormone release inhibitor</Class><Class id="396">Immunosuppressant</Class><Class id="4007">Antidiarrhoeal</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62253">Anticancer hormone</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="70">Anticonvulsant agent</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="902">Orally disintegrating tablet</Technology><Technology id="80">Peptide</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="745">Suspension</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>429</PatientCountEnrollment><PatientCountEvaluable>429</PatientCountEvaluable><DateStart>2006-12-31T00:00:00Z</DateStart><DateEnd type="actual">2013-06-13T00:00:00Z</DateEnd><DateChangeLast>2018-04-21T11:52:56Z</DateChangeLast><DateAdded>2008-10-03T12:41:24Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Novartis Pharmaceuticals</Affiliation><Name>Novartis Pharmaceuticals</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Advanced (unresectable or metastatic) carcinoid tumor&lt;/li&gt;&lt;li&gt;Confirmed low-grade or intermediate-grade neuroendocrine carcinoma&lt;/li&gt;&lt;li&gt;Documented progression of disease within 12 months prior to enrollment&lt;/li&gt;&lt;li&gt;Measurable disease determined by triphasic CT scan or MRI&lt;/li&gt;&lt;li&gt;Patients must have a history of secretory symptoms, which is defined as symptoms of diarrhoea or flushing or both which were attributed to their carcinoid tumour. However, these symptoms need not be active at the time of enrollment&lt;/li&gt;&lt;li&gt;Adequate bone marrow function as shown by:&lt;ul&gt;&lt;li&gt;ANC &gt;/= 1.5 x 10 high 9/l&lt;/li&gt;&lt;li&gt;Platelets &gt;/= 100 x 10 high 9/l, Hb &gt; 9 g/dl&lt;/li&gt;&lt;li&gt;Adequate liver function as shown by:&lt;ul&gt;&lt;li&gt;Serum bilirubin&amp;lt;/= 1.5 x ULN&lt;/li&gt;&lt;li&gt;INR&amp;lt; 1.3 (or &amp;lt; 3 on anticoagulants)&lt;/li&gt;&lt;li&gt;ALT and AST&amp;lt;/= 2.5x ULN (&amp;lt;/=  5 x ULN in patients with liver metastases)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Adequate renal function&lt;ul&gt;&lt;li&gt;Serum creatinine&amp;lt;/= 1.5 x ULN&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Fasting serum cholesterol&amp;lt;/= 300 mg/dL OR 7.75 mmol/l AND fasting triglycerides &amp;lt;/= 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication&lt;/li&gt;&lt;li&gt;Performance Status 0 to 2 on the WHO scale&lt;/li&gt;&lt;li&gt;Adult male or female patients &gt;/= to 18 years of age&lt;/li&gt;&lt;li&gt;Women of childbearing potential must have had a negative serum or urine pregnancy test within 48 hours of the administration of the first study treatment&lt;/li&gt;&lt;li&gt;Patients who give a written informed consent obtained according to local guidelines&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoma, or small cell carcinoma&lt;/li&gt;&lt;li&gt;Hepatic artery embolization within the last 6 months or cryoablation of hepatic metastasis within 2 months of enrollment&lt;/li&gt;&lt;li&gt;Previous treatment with mTOR inhibitors (sirolimus, temsirolimus,&lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;)&lt;/li&gt;&lt;li&gt;Intolerance or hypersensitivity to&lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;, or other rapamycins&lt;/li&gt;&lt;li&gt;Chronic treatment with corticosteroids or other immunosuppressive agent&lt;/li&gt;&lt;li&gt;Other primary cancer within  three years&lt;/li&gt;&lt;li&gt;Patients who have any severe and/or uncontrolled medical conditions such as:&lt;ul&gt;&lt;li&gt;Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction&amp;lt;/= 6 months prior to randomization, serious uncontrolled cardiac arrhythmia&lt;/li&gt;&lt;li&gt;Active or uncontrolled severe infection&lt;/li&gt;&lt;li&gt;Cirrhosis, chronic active hepatitis or chronic persistent hepatitis&lt;/li&gt;&lt;li&gt;Severely impaired lung function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less t rest on room air)&lt;/li&gt;&lt;li&gt;Active, bleeding diathesis&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients with a known history of HIV seropositivity&lt;/li&gt;&lt;li&gt;Patients who have a history of another primary malignancy&amp;lt;/= 3 years, with the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix&lt;/li&gt;&lt;li&gt;Female patients who are pregnant or nursing (lactating), or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes&lt;/li&gt;&lt;li&gt;Patienst who have recived an investigative drug or therapy within the 30 days prior to screening&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Progression free survival (PFS) as per adjudicated Central Radiology Review: progression free survival (PFS) is defined as the time from randomization to the date of first documented disease progression or death from any cause. The primary analysis of PFS was based on the independent central adjudicated assessment using Kaplan-Meier method</Description><Timeframe>Time from randomization to dates of disease progression, death from any cause or last tumor assessment, reported between day of first patient randomized, 10 January 2007, until cut-off date 02 April 2010</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Best overall response rate as per adjudicated Central Radiology Review based on Response Evaluation Criteria in Solid Tumors (RECIST): the best overall response rate is defined as the percentage of patients having achieved confirmed complete response + partial response. Complete response (CR) = at least two determinations of CR at least 4 weeks apart before progression. Partial response (PR) = at least two determinations of PR or better at least 4 weeks apart before progression</Description><Timeframe>Time from randomization to dates of disease progression, death from any cause or last tumor assessment, reported between day of first patient randomized, 10 January 2007, until cut-off date 02 April 2010</Timeframe></Measure><Measure><Description>Progression Free Survival (PFS) as Per Adjudicated Central Review by Baseline 5-hydroxyindoleacetic Acid (5-HIAA) Level: 5-HIAA levels in urine are frequently elevated in patients with advanced carcinoid tumors. Baseline levels of 5-HIAA in urine were defined as &amp;apos;High&amp;apos; if they exceeded the median value, and; if they were lower than or equal to the median</Description><Timeframe>If elevated at baseline, evaluated every cycle visit (28 days/cycle) reported between day of first patient randomised, 10 January 2007, until cut-off date 02 April 2010</Timeframe></Measure><Measure><Description>Progression Free Survival (PFS) as per adjudicated Central Review by change from baseline chromogranin A (CgA) and 5-hydroxyindoleacetic acid (5-HIAA): serum CgA and 5-HIAA levels in urine are frequently elevated in patients with advanced carcinoid tumors. Baseline levels of serum CgA were characterized relative to the upper limited of normal (ULN). CgA levels exceeding 2 x ULN were considered to be 'elevated'; otherwise considered as "non-elevated". Baseline levels of 5-HIAA in urine were defined as 'high' if they exceeded the median value, and 'low' if they were lower than or equal to the median</Description><Timeframe>If elevated at baseline, evaluated every cycle visit (28 days/cycle)</Timeframe></Measure><Measure><Description>Overall survival using Kaplan-Meier methodology: overall survival was defined as the time from the date of randomization to the date of death from any cause. If a patient was not known to have died, survival was censored at the date of last contact. Kaplan-Meier methodology was used to estimate the median overall survival for each treatment group</Description><Timeframe>The date of randomization to the date of death</Timeframe></Measure><Measure><Description>Number of Patients With Adverse Events (AEs), Clinically Notable AE, Death, Serious Adverse Events (SAEs) (Double-Blind Phase): AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards</Description><Timeframe>From first day of treatment up to 28 days after last day of treatment in double blind</Timeframe></Measure><Measure><Description>Number of Patients With Adverse Events (AEs), Clinically Notable AE, Death, Serious Adverse Events (SAEs) (Open Label Phase): AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards</Description><Timeframe>From first day of treatment up to 28 days after last day of treatment in double blind</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In October 2010, results were presented. The most frequent all grade drug-related adverse events with &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR were stomatitis, rash, fatigue and diarrhea; most were grade 1/2. Stomatitis (6.5%), fatigue (6.5%), diarrhea (6%), infections/infestations (5.1%) and hyperglycemia (5.1%) were the grade3/4 adverse events  (&gt;/=  5%) observed in patients treated with &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR    [&lt;ulink linkType="Reference" linkID="1137765"&gt;1137765&lt;/ulink&gt;]. In February 2011, similar results were presented. Most frequent all grade drug-related adverse events with &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR also included nausea and infections [&lt;ulink linkType="Reference" linkID="1167084"&gt;1167084&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, further results were presented.  Stomatitis (61.9 versus 14.2%), rash (37.2 versus 12.3%), fatigue (31.6 versus 24.2%), diarrhea (27.4 versus 15.6%), nausea (20.0 versus 16.1%), and infections and infestations (20.0 versus 7.1%) in  &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR versus placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR groups, respectively, were the commonly observed adverse events (AEs) in the study.  The most frequent drug-related grade 3 to 4 AEs were fatigue (6.5 versus 2.8), diarrhea (6.0  versus 2.4), and hyperglycemia (5.1  versus 0.5) in   &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR      versus placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR  groups, respectively. Rate of drug-related AEs leading to discontinuation was 19.5% for &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR versus 3.8% for placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR [&lt;ulink linkType="Reference" linkID="1195559"&gt;1195559&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1196459"&gt;1196459&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1215915"&gt;1215915&lt;/ulink&gt;]. Similar results were presented in September 2011.   Fatigue, dyspnea, diarrhea, deteriorating general physical health, interstitial lung disease, pneumonia and pneumonitis were the most commonly reported AEs that led to discontinuation of   &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR  therapy    [&lt;ulink linkType="Reference" linkID="1224029"&gt;1224029&lt;/ulink&gt;]. Similar results were published in December 2011  [&lt;ulink linkType="Reference" linkID="1251891"&gt;1251891&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2011,  results from an exploratory analysis of lung NET patients were presented. All patients in the &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; group and 90.9% of patients in the placebo group experienced AEs of any grade. Asthenia, diarrhea, nausea and stomatitis were some of the most frequently reported AEs (all grades) in &gt;/= 10% of patients in &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; group. AEs of grade 3/4 intensity were observed in 23 patients in the &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; group compared with 3 patients in the placebo group. Grade 3/4 infections and infestations were reported in six &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR-treated patients, compared with one placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR-treated patient with grade 3 infection. The most common AEs of grade 3/4 intensity were infections and infestations, and diarrhea in patients with lung NET  [&lt;ulink linkType="Reference" linkID="1224037"&gt;1224037&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012,  results from a pooled meta-analysis of five phase II/III cancer trials (Soria et al; &lt;ulink linkType="Protocol" linkID="34579"&gt;RADIANT-1&lt;/ulink&gt;; &lt;ulink linkType="Protocol" linkID="44117"&gt;RECORD-1&lt;/ulink&gt;; RADIANT-2; &lt;ulink linkType="Protocol" linkID="35751"&gt;RADIANT-3&lt;/ulink&gt;), assessing the relationship between &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; 10 mg/day exposure and safety and efficacy, tumor size and Cmax and progression free survival (PFS) of the drug, were presented. Of the 938 patients in the safety set, 867 had more than one adverse event of any grade, of which 56.5% were commonly stomatitis/oral mucositis/ulcers. The risk of adverse events was decreased by dose adjustment. Adverse events of &gt;/= grade 3 included bleeding events (2.9%), hematopoiesis decreased (16.4%), hepatic events (1.6%), infections and infestations (11.2%), metabolic events (11.5%), pulmonary events (2.6%), rash and similar events (1.0%), renal events (3.7%), stomatitis/oral mucositis/ulcers (5.7%) and thromboembolic events (3.4%)     [&lt;ulink linkType="Reference" linkID="1299649"&gt;1299649&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, results of post hoc analysis  showed that in patients with colorectal NETs the combination of &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR was generally well tolerated. The most common adverse events reported were rash and stomatitis [&lt;ulink linkType="Reference" linkID="1411567"&gt;1411567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, results from ECCO-ESMO-ESTRO were presented. The most common AEs in the open-label safety set was observed to be diarrhea (47.1%), stomatitis (37.6%), nausea (35.3%), edema (35.3%), fatigue (34.7%) and rash. Adverse events irrespective of relationship to treatment (reported by &gt;/= 15% of patients) in &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR (double-blind phase) and &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR (open-label phase) were diarrhea (53 and 47.1%), stomatitis (50.7 and 37.6%), fatigue (48.8 and 34.7%), nausea (43.3 and 35.3%), edema (43.3 and 35.3%), rash (40.9 and 34.1%), abdominal pain (33.0 and 27.1%), vomiting (33.0 and 19.4%), headache (30.2 and 18.2%), decreased appetite (29.8 and 20.0%), dyspnea (28.8 and 14.7%),  cough (27.9 and 20.6%), anemia (27.9 and 21.8%), weight decreased (27.4 and 18.8%), asthenia (23.7 and 15.3%), hypokalemia (23.7 and 15.3%), pyrexia (20.9 and 18.8%), pruritus (19.5 and 10.6%), dysgeusia (19.5 and 17.6%), hyperglycemia (19.1 and 14.1 %), arthralgia (17.7 and 11.2%), thrombocytopenia (16.3 and 9.4%), epistaxis (15.3 and 14.1%), back pain (15.3 and 10.6%) and pain in extremity (14.9 and 10.0%), respectively. A total of 253 (58.9%) patients died. In the &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; treatment group, the incidence of death was slightly higher(+5.3%) when compared to placebo group (133 [61.6%] deaths in the &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR arm and 120 [56.3%] in the placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR arm). Study drug discontinuation attributable to AEs were observed more often in the &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; treatment group (65 patients [30.2%] versus 17 patients [8.1%] for the placebo group) in the double-blind phase. Dyspnea, fatigue (each reported in five patients [2.3%]), diarrhea, pneumonia, interstitial lung disease, pneumonitis, and general physical health deterioration (each reported in four patients [1.9%]) were the most commonly reported AEs leading to study drug discontinuation in the &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;  treatment group. Abdominal pain and stomatitis (each reported in four patients [2.4%]) and diarrhea (three patients [1.8%]) were the most commonly reported AEs leading to study drug discontinuation in the open-label phase [&lt;ulink linkType="Reference" linkID="1480339"&gt;1480339&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, pooled results from the trials (&lt;ulink linkType="Protocol" linkID="44117"&gt;RECORD-1&lt;/ulink&gt;, RADIANT-2, &lt;ulink linkType="Protocol" linkID="35751"&gt;RADIANT-3&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="49221"&gt;BOLERO-2&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="61712"&gt;BOLERO-3&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="35723"&gt;EXIST-1,&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="35724"&gt;EXIST -2&lt;/ulink&gt;) were presented. In oncology patients, the incidence of crude stomatitis was 66.9% and appeared earlier, among them 8.6% had grade 3/4. In 1.7% of patients, the stomatitis led to discontinuation. In 40% of patients, the recurrence was reported and was less rapidly appeared. In TSC patients, the similar results were observed. In &lt;ulink linkType="Protocol" linkID="49221"&gt;BOLERO-2&lt;/ulink&gt; and &lt;ulink linkType="Protocol" linkID="35751"&gt;RADIANT-3&lt;/ulink&gt; trials, an association between stomatitis and PFS was observed which was maintained after correcting for exposure. In &lt;ulink linkType="Protocol" linkID="44117"&gt;RECORD-1&lt;/ulink&gt;, similar trend was observed but not in &lt;ulink linkType="Protocol" linkID="61712"&gt;BOLERO-3&lt;/ulink&gt; or RADIANT-2 [&lt;ulink linkType="Reference" linkID="1562411"&gt;1562411&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, results were published. Increased everolimus Cmin was associated with risk of pulmonary or metabolic events [&lt;ulink linkType="Reference" linkID="1923436"&gt;1923436&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2017, results of final overall were published. During the open-label phase, diarrhea, fatigue and stomatitis were the most frequent drug-related grade 3 or 4 AEs reported in 5.3, 4.7 and 4.1% of patients, respectively. In the everolimus arm, deaths related to pulmonary or cardiac failure were observed more frequently [&lt;ulink linkType="Reference" linkID="2025766"&gt;2025766&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate whether &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;   10 mg/day added to treatment with &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; depot, prolongs progression free survival compared to treatment with &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; alone in patients with advanced carcinoid tumor. &lt;/para&gt;&lt;para&gt;The main objective of the trial was to determine whether treatment with RAD-001 10 mg/d plus Sandostatin LAR Depot prolongs the progression free survival (PFS) compared to treatment with Sandostatin LAR Depot alone in patients with advanced carcinoid tumor.&lt;/para&gt;&lt;para&gt;Secondary objectives of the trial were:&lt;br/&gt;To evaluate the anti-tumor effect of RAD-001 on other tumor endpoints (best overall response rate - complete response [CR] and partial response [PR], response duration).&lt;br/&gt;To compare overall survival (OS) between the study arms.&lt;br/&gt;To compare changes from baseline in 5-hydroxyindoleacetic acid (5 HIAA) and chromogranin A (CgA).&lt;br/&gt;To determine the safety and tolerability of the combination of RAD001 (10 mg/d) plus Sandostatin LAR Depot.&lt;br/&gt;To characterize the pharmacokinetics of RAD-001 and Sandostatin LAR Depot administered in combination in carcinoid indications.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In July 2010, data from the trial were reported showing that the primary endpoint was closely missed (PFS: p = 0.026 for &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; versus p = 0.024 predefined) [&lt;ulink linkType="Reference" linkID="1116461"&gt;1116461&lt;/ulink&gt;]. Similar results were presented in October 2010 [&lt;ulink linkType="Reference" linkID="1137765"&gt;1137765&lt;/ulink&gt;].  In February 2011, similar results were presented [&lt;ulink linkType="Reference" linkID="1167084"&gt;1167084&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Findings from further analyses of the study data were presented in October 2010 at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy. Analyses were conducted using a statistical model to adjust for imbalances in baseline characteristics between the two treatment arms and inconsistencies between the review of radiology scans for disease progression. Findings demonstrated that &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR provided a clinically meaningful extension in the median time without tumor growth from 11.3 to 16.4 months when compared with placebo plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR ( p = 0.026). The results demonstrated that &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR provided a significant reduction in the risk of disease progression by 40%, versus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR alone (p = 0.0014) [&lt;ulink linkType="Reference" linkID="1137765"&gt;1137765&lt;/ulink&gt;]. In February 2011, similar results were presented [&lt;ulink linkType="Reference" linkID="1167084"&gt;1167084&lt;/ulink&gt;]. Similar results were presented in June 2011   [&lt;ulink linkType="Reference" linkID="1215915"&gt;1215915&lt;/ulink&gt;]. Similar results were published in December 2011  [&lt;ulink linkType="Reference" linkID="1251891"&gt;1251891&lt;/ulink&gt;]. In June 2012, similar results were presented [&lt;ulink linkType="Reference" linkID="1303395"&gt;1303395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, similar and further results  from analysis of primary tumor site were presented. Small intestine, lung, and colorectal were the primary tumor sites in 224 (111     &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR; 113 placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR), 44 (33     &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR; 11 placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR), and 39 (19     &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR; 20 placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR) patients. A total of 123 patients on placebo crossed over   to &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR therapy during disease progression.   &lt;ulink linkType="Drug" linkID="13340"&gt;Everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR induced improvement in median PFS by 4.6, 8.0, and 23.3 months in small intestine, lung and colorectal subgroups respectively. Median 12-month, and 18-month PFS was     60.6 versus 48.7%, and  47.2 versus 37.4%  in     &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR versus placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR groups, respectively. Median follow-up in overall patients was 28 months and median duration of treatment was 37 versus  36.6 weeks in &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR  versus  placebo  + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR groups, respectively  [&lt;ulink linkType="Reference" linkID="1196459"&gt;1195558&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2011, results were also presented from exploratory analysis of patients who received prior somatostatin analog (SSA) therapy and those who did not. A total of 79% of enrolled patients undergone  SSA therapy before study entry (173 were randomized to  &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR  and  166 were randomized to placebo  + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR). Patients who received prior SSA were found to have  elevated chromogranin  A (CgA) and 5-hydroxyindoleacetic acid (5-HIAA) baseline levels (68 and 47% of total population, respectively) than those who did not  (59 and 31% of total population, respectively). &lt;ulink linkType="Drug" linkID="13340"&gt;Everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR induced  a prolonged PFS (25.2 months) in SSA-naive patients compared to  patients with previous SSA therapy (14.3 months) and total population (16.4 months) [&lt;ulink linkType="Reference" linkID="1195559"&gt;1195559&lt;/ulink&gt;], Similar results were published in 2015 [&lt;ulink linkType="Reference" linkID="1720502"&gt;1720502&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Further results  in June 2011, showed that median PFS in patients with elevated chromogranin A (CgA) was 13.9 versus 8.4 months in  &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR  versus placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR  groups, respectively.   Median PFS in patients with non-elevated CgA was 31.3 versus 20.1 months in    &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR versus placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR groups, respectively (p = 0.14). &lt;ulink linkType="Drug" linkID="13340"&gt;Everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR induced greater  reductions in serum CgA and 5-HIAA levels  [&lt;ulink linkType="Reference" linkID="1196459"&gt;1196459&lt;/ulink&gt;].  In the &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; and placebo groups, 164 and 146 patients, respectively, were evaluable for responses. Serum CgA and 24-h  urinary 5-HIAA were reduced by &gt;/= 50% from baseliine in 45.7  versus  28.8%, and 60.7 versus  46.8% of patients in     &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR versus placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR groups, respectively. After first cycle of treatment, the least square mean estimates for the ratios  of change from baseline  in CgA and 5-HIAA  levels were  0.85 and 0.84 in &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR versus placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR groups, respectively.  &lt;ulink linkType="Drug" linkID="13340"&gt;Everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR   induced  and maintained positive effects  over the following  treatment cycles [&lt;ulink linkType="Reference" linkID="1196696"&gt;1196696&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2011, results from a multivariate analysis conducted  to determine the factors that significantly influence PFS were presented. Analysis showed that significant prognostic factors for PFS were treatment (&lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; versus placebo: 16.43 versus 11.3 months; p = 0.001), WHO performance status (0 versus &gt;/= 1: 16.62 versus 11.10 months; p = 0.007), lung as primary site (yes versus no: 10.61 versus 14.23 months; p = 0.044), baseline CgA (elevated versus non-elevated: 11.33 versus 26.84 months; p &amp;lt; 0.001), and bone involvement (yes versus no: 8.31 versus 15.38  months; p = 0.022), respectively [&lt;ulink linkType="Reference" linkID="1196675"&gt;1196675&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1215915"&gt;1215915&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Similar results were presented in September 2011. PFS was significantly longer for patients with nonelevated baseline CgA biomarker levels compared to  patients with elevated baseline CgA biomarker levels (26.8  versus 11.3 months; p &amp;lt; 0.001).  Biomarker analyses of both treatment arms  revealed that baseline CgA (&amp;lt;/= 2 x  ULN versus &amp;gt; 2 x   ULN; p &amp;lt; 0.001) had a prognostic effect on PFS. PFS was significantly longer with  &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;  treatment for patients with    elevated baseline 5-HIAA biomarker levels (16.4  versus 9.7 months; p = 0.007)  compared to placebo treatment. PFS was also improved in patients with nonelevated baseline 5-HIAA biomarker levels treated with  &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;  plus  &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;  LAR compared to patients who received placebo +  &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;  LAR, but not statistically significantly prolonged (20.1 versus 13.0 months; p = 0.11). PFS was significantly improved in patients who experienced early CgA and 5-HIAA response within the first month of treatment (first cycle) compared to nonresponders (20.0  versus 10.8 months; p &amp;lt; 0.001 and 17.1  versus 12.0 months; p = 0.193, respectively)  [&lt;ulink linkType="Reference" linkID="1224028"&gt;1224028&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Further results were presented in September 2011. After treatment, the median PFS by central review was 16.4 and 11.3 months in the   &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;   +   &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;   LAR and placebo +   &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;   LAR groups, respectively, demonstrating a 23% reduction in the risk for progression (primary endpoint; p = 0.026). The PFS by the local investigator assessment was 12 and 8.6 months in the   &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;   +   &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;   LAR and placebo +   &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;   LAR groups, respectively, with a 22% reduction in risk for progression (p = 0.018). More number of patients in the   &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;   +   &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;   LAR group (n = 100) had died than in the placebo +   &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;   LAR group (n = 85). The median overall survival was 30.5 and 33.5 months for the   &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;   +   &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;   LAR and placebo +   &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;   LAR groups, respectively, with no statistically significant difference between the treatment arms. The median dose intensity of   &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;   and placebo were 9.5 and 10.0 mg/day [&lt;ulink linkType="Reference" linkID="1224029"&gt;1224029&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2011,  results from an exploratory analysis to assess the effect of previous somatostatin analog (SSA) therapy on  PFS were presented. Of the enrolled patients, 339 received previous SSA therapy, of whom 173 were assigned to    &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;    group and 166 were assigned to placebo group.   After treatment with    &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;   +   &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;   LAR, PFS was 14.3 months in patients with previous SSA therapy and 25.2 months in those with no previous SSA therapy. Excluding the small intestine as primary site, PFS in patients treated with    &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;   +   &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt;    LAR was similar regardless of previous SSA therapy. With small intestine as the primary tumor site, the overall median PFS was 18.63 and 14.03 months in the    &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;    and placebo groups, respectively, and was longer in the    &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;    group compared with placebo regardless of previous SSA therapy. The median PFS was 22.74 months in SSA naive patients with small intestine neuroendocrine tumor (NET)  receiving placebo   [&lt;ulink linkType="Reference" linkID="1224031"&gt;1224031&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2011,  results from an exploratory analysis of lung NET patients were presented. Of 429 patients, 44 had lung NET; a total of 33 and 11 patients were included in the &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; and placebo groups in this analysis, respectively. The median progression-free survival (primary endpoint) in the &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; and placebo groups was 13.63 and 5.59 months, respectively. &lt;ulink linkType="Drug" linkID="13340"&gt;Everolimus&lt;/ulink&gt; group was associated with 28% reduction in the estimated risk for progression (p = 0.228).    A decrease in the target lesion from baseline was observed in 67 and 27% of patients in &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; and placebo groups, respectively  [&lt;ulink linkType="Reference" linkID="1224037"&gt;1224037&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, results from a multivariate analysis that included biomarkers in this study of &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR plus &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; or placebo in patients with advanced neuroendocrine tumors (NET), were presented. In CgA elevated biomarker, median progression free survival (PFS) was 13.9 months with  &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;, compared to placebo at 8.4 months. In CgA non-elevated biomarker, median PFS was 31.3 versus 20.1 months in these groups, respectively. The exploratory analyses adjusted for the prognostic factors suggested significant benefit for &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; therapy with a 38% reduction in risk of progression compared with placebo (p = 0.003). A significantly longer median PFS (months) was in patients with non-elevated CgA (26.8 versus 11.3 in elevated CgA; p &amp;lt; 0.001) and non-elevated 5-HIAA (16.6 versus 11.1 in elevated 5-HIAA; p &amp;lt; 0.001). The median PFS (months) of patients in respective &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; versus placebo groups was: age (14.3 versus 12.2; p = 0.013), WHO PS (16.6 versus 11.1; p = 0.004), liver involvement (13.8 versus not reached; p = 0.018), bone metastases (8.3 versus 15.4; p &amp;lt; 0.001), and lung as primary site (10.6 versus 14.2; p = 0.061), respectively; the analyses indicated them as potentially prognostic factors. Significant prognostic factors for PFS according to multivariate analysis included baseline CgA (p &amp;lt; 0.001), WHO PS (p = 0.006), bone involvement (p = 0.020), and lung as primary site (p = 0.044) for respective &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; versus placebo groups  [&lt;ulink linkType="Reference" linkID="1299536"&gt;1299536&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012,  results from a pooled meta-analysis of five phase II/III cancer trials (Soria et al; &lt;ulink linkType="Protocol" linkID="34579"&gt;RADIANT-1&lt;/ulink&gt;; &lt;ulink linkType="Protocol" linkID="44117"&gt;RECORD-1&lt;/ulink&gt;; RADIANT-2; &lt;ulink linkType="Protocol" linkID="35751"&gt;RADIANT-3&lt;/ulink&gt;), assessing the relationship between &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; 10 mg/day exposure and safety and efficacy, tumor size and Cmax and progression free survival (PFS) of the drug, were presented. In the 945 patients, median Cmin normalized to the 10 mg dose was stable over time. Likelihood of tumor size reduction was increased by the two-fold increase in &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; exposure, which was also associated with reduced PFS risk and increased risk of high grade adverse events     [&lt;ulink linkType="Reference" linkID="1299649"&gt;1299649&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, results showed that the median Cmin value of &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; was found to be stable over time; the Cmin values with the dose of 10 mg/day were found to be similar to the values observed in an earlier study. The inter-subject variability in Cmin values ranged from 32.9 to 130%. Regardless of the treatment group, the predose concentrations of &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR were found to be stable during the study period. The Cmin value of &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR was increased on co-administration of &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR with a geometric mean (GM) ratio (&lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;/placebo) of 1.47. The GM Cmin values of &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR in &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; and placebo groups were 5.19 and 3.53 ng/ml, respectively. Statistically significant impact of &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; log Cmin on the prolongation of PFS was not found in either &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; (p = 0.17) or the placebo (p = 0.13) arm. At the decreasing exposure of the other drug, the impact of the respective increase in Cmin on PFS was more prominent. Regardless of &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; exposure, the progression risk was reduced consistently when Cmin of &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; was increased by two-fold [&lt;ulink linkType="Reference" linkID="1303395"&gt;1303395&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2013, results of post hoc analysis  showed that a significantly longer median progression free survival (PFS) (29.9 months; n = 19) was seen in patients with colorectal NETs (neuroendocrine tumors), receiving &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR (long-acting repeatable) than did those receiving placebo plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR (6.6 months; n = 20). There was a significant reduction in the treatment risk for disease progression (p = 0.011) in &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR group. Tumor shrinkage was more frequently noted in the &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR arm than in the placebo plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR arm (67 versus 37%, respectively), although no objective responses were observed [&lt;ulink linkType="Reference" linkID="1411567"&gt;1411567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, results from ECCO-ESMO-ESTRO were presented. In patients randomly assigned to receive &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR and placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR and switched to open-label &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt;, the median duration of total &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; exposure (including both the double-blind and the open-label phases) was 37 weeks (range 1 to 270) and 34.1 weeks (1 to 200), respectively. For &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR and placebo + &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR, the median OS after 253 events was 29.2 (23.8 to 35.9) and 35.2 (30.0 to 44.7) months (hazard ration [HR] = 1.17), respectively [&lt;ulink linkType="Reference" linkID="1480339"&gt;1480339&lt;/ulink&gt;]. Similar results of finall overaal survival after 271 events were published in July 2017 [&lt;ulink linkType="Reference" linkID="2025766"&gt;2025766&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, clinical data were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco, CA. In placebo plus octreotide LAR group, the median progression-free survival (PFS) in patients naive to treatment with a somatostatin analog was 13.6 months compared with 11.1 months for treatment-experienced patients. By primary tumor location, treatment-naive patients had PFS of 5.7, 22.2 months and not reached for the foregut, midgut and hindgut, respectively; these respective values for treatment-experienced patients were 8.7, 12 and 6.6 months. The median overall survival was 35.8 months in the overall population, 50.6 months in treatment-naive patients and 33 months in treatment-experienced patients [&lt;ulink linkType="Reference" linkID="1517517"&gt;1517517&lt;/ulink&gt;]. Similar results were published in 2014 [&lt;ulink linkType="Reference" linkID="1560961"&gt;1560961&lt;/ulink&gt;]. Similar results were published in 2015 [&lt;ulink linkType="Reference" linkID="1720502"&gt;1720502&lt;/ulink&gt;]. Similar results were published in post hoc analysis in December 2015 [&lt;ulink linkType="Reference" linkID="1734381"&gt;1734381&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, pooled results from the trials (&lt;ulink linkType="Protocol" linkID="44117"&gt;RECORD-1&lt;/ulink&gt;, RADIANT-2, &lt;ulink linkType="Protocol" linkID="35751"&gt;RADIANT-3&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="49221"&gt;BOLERO-2&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="61712"&gt;BOLERO-3&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="35723"&gt;EXIST-1&lt;/ulink&gt;, and &lt;ulink linkType="Protocol" linkID="35724"&gt;EXIST -2&lt;/ulink&gt;) were presented.  Longer PFS was observed in patients treated with &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; compared with placebo, regardless of stomatitis incidence. Relationship between stomatitis and response was concluded by very few patients with TSC [&lt;ulink linkType="Reference" linkID="1562411"&gt;1562411&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, results of an analysis were published. The aim of this analysis was to characterize the effects of everolimus co-administration on octreotide LAR pharmacokinetics and its relationship with efficacy and safety. Octreotide Cmin was increased by concomitant everolimus with a geometric mean ratio (everolimus/placebo) of 1.47. When everolimus Cmin was increased twofold, risk for progression was consistently reduced regardless of octreotide exposure (hazard ratio [HR] = 0.74 and 0.54 for 6 and 4 ng/ml octreotide, respectively). There was no impact on efficacy as co-administration of everolimus plus octreotide LAR increased octreotide Cmin [&lt;ulink linkType="Reference" linkID="1923436"&gt;1923436&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2017, results were published. Octreotide in combination with everolimus demonstrated a clinically meaningful 5.1-month improvement in progression-free survival (PFS) in patients with advanced functional neuroendocrine tumors [&lt;ulink linkType="Reference" linkID="1923436"&gt;1923436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2017, further results of final overall were published. For baseline covariates, adjusted HR was found to be 1.08  [&lt;ulink linkType="Reference" linkID="2025766"&gt;2025766&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be  randomized into one of two arms.&lt;br/&gt;Arm 1: &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; would be administered in accordance with a 10 mg/day dosing regimen (two 5 mg tablets) in conjunction with &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; 30 mg im every 28 days. Patients would be  treated until progression or unacceptable toxicity. Each treatment cycle would last for 28 days. Patients would receive their first dose of &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; at cycle 1, day 1. Administration of &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; was performed every 28 days (+/- 4 days) starting on cycle 1, day 1.&lt;br/&gt;Arm 2: matching placebo would be  administered in accordance with a 10 mg/day dosing regimen (two 5 mg tablets) in conjunction with &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; 30 mg im every 28 days. Patients would be treated until progression or unacceptable toxicity; Each treatment cycle woudl last 28 days. Patients would receive their first dose of matching placebo at cycle 1, day 1. Administration of &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; would be  performed every 28 days (+/- 4 days) starting on cycle 1, day 1.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients  (n = 429) were randomized in  a 1 : 1 ratio  to receive either  &lt;ulink linkType="Drug" linkID="13340"&gt;everolimus&lt;/ulink&gt; 10 mg/day po   plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR 30 mg im (n = 216) or placebo plus &lt;ulink linkType="Drug" linkID="3735"&gt;octreotide&lt;/ulink&gt; LAR  30 mg im (n = 213) q28d  [&lt;ulink linkType="Reference" linkID="1137765"&gt;1137765&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1167084"&gt;1167084&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1196459"&gt;1195558&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1195558"&gt;1195559&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1196459"&gt;1196459&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1196675"&gt;1196675&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1196696"&gt;1196696&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1215915"&gt;1215915&lt;/ulink&gt;],   [&lt;ulink linkType="Reference" linkID="1224028"&gt;1224028&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1224029"&gt;1224029&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1224031"&gt;1224031&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1224037"&gt;1224037&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1251891"&gt;1251891&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1299536"&gt;1299536&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1303395"&gt;1303395&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1480339"&gt;1480339&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1720502"&gt;1720502&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1734381"&gt;1734381&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2025766"&gt;2025766&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>everolimus + octreotide</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="1016">Stomatitis</Indication><CountPatientsAffectedPercentage>61.9</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>86.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>27.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="1821">Hyperglycemia</Indication><CountPatientsAffectedPercentage>5.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>20.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3020">Skin rash</Indication><CountPatientsAffectedPercentage>37.2</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3062">Death</Indication><CountPatientsTotal>216</CountPatientsTotal><CountPatientsAffected>100</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="746">Infectious disease</Indication><CountPatientsAffectedPercentage>20.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsAffectedPercentage>31.6</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>placebo + octreotide</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="1016">Stomatitis</Indication><CountPatientsAffectedPercentage>14.2</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>15.6</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>16.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3020">Skin rash</Indication><CountPatientsAffectedPercentage>12.3</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3062">Death</Indication><CountPatientsTotal>213</CountPatientsTotal><CountPatientsAffected>85</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="746">Infectious disease</Indication><CountPatientsAffectedPercentage>7.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsAffectedPercentage>24.2</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>everolimus + octreotide LAR (double-blind)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="1016">Stomatitis</Indication><CountPatientsAffectedPercentage>50.7</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>53.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsAffectedPercentage>33.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="148">Headache</Indication><CountPatientsAffectedPercentage>30.2</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>43.3</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2400">Dyspnea</Indication><CountPatientsAffectedPercentage>28.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2955">Weight loss</Indication><CountPatientsAffectedPercentage>27.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3020">Skin rash</Indication><CountPatientsAffectedPercentage>40.9</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3038">Appetite loss</Indication><CountPatientsAffectedPercentage>29.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3472">Abdominal pain</Indication><CountPatientsAffectedPercentage>33.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="402">Edema</Indication><CountPatientsAffectedPercentage>43.3</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="82">Cough</Indication><CountPatientsAffectedPercentage>27.9</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsAffectedPercentage>48.8</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>everolimus + octreotide LAR (open-label)</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="1016">Stomatitis</Indication><CountPatientsAffectedPercentage>37.6</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>47.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="110">Emesis</Indication><CountPatientsAffectedPercentage>19.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="148">Headache</Indication><CountPatientsAffectedPercentage>18.2</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>35.3</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2400">Dyspnea</Indication><CountPatientsAffectedPercentage>14.7</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2955">Weight loss</Indication><CountPatientsAffectedPercentage>18.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3020">Skin rash</Indication><CountPatientsAffectedPercentage>34.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3038">Appetite loss</Indication><CountPatientsAffectedPercentage>20.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3472">Abdominal pain</Indication><CountPatientsAffectedPercentage>27.1</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="402">Edema</Indication><CountPatientsAffectedPercentage>35.3</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="82">Cough</Indication><CountPatientsAffectedPercentage>21.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="829">Fatigue</Indication><CountPatientsAffectedPercentage>34.7</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="57541">everolimus</Intervention><Treatments><Treatment><Dose>10 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="57660">octreotide acetate (long-acting formulation), Novartis</Intervention><Treatments><Treatment><Dose>30 milligram</Dose><Route>Intramuscular</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Name>Novartis Investigative Site</Name><Address1>East Melbourne</Address1><Address3> 3002</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Heidelburg</Address1><Address3> 3084</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Herston</Address1><Address3> 4029</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Woodville</Address1><Address3> 5011</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Herston</Address1><Address2>Queensland</Address2><Address3>4029</Address3><CountrySubDivision>Queensland</CountrySubDivision><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Kogarah</Address1><Address2>New South Wales</Address2><Address3>2217</Address3><CountrySubDivision>New South Wales</CountrySubDivision><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>South Brisbane</Address1><Address2>Queensland</Address2><Address3>4101</Address3><CountrySubDivision>Queensland</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Belgium"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Clinical Trial Information Desk</Name></Contact></Contacts></Site><Site><Name>Novartis Investigative Site</Name><Address1>Bruxelles</Address1><Address3>1070</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Canada"><Sites><Site><Name>Novartis Investigative Site</Name><Address1>London</Address1><Address2>Ontario</Address2><Address3>N6A 4L6</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><Address3>H1T 2M4</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Montreal</Address1><Address2>Quebec</Address2><Address3>H2X 1P1</Address3><CountrySubDivision>Quebec</CountrySubDivision><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M5G 2M9</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Czech Republic"><Sites><Site><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Praha 2</Address1><Address3>128 08</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Pribram</Address1><Address3>261 95</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Berlin</Address1><Address3>13353</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Hamburg</Address1><Address3>20246</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Denmark"><Sites><Site><RecruitmentStatus id="6">Terminated</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><Name>Novartis Investigative Site</Name><Address1>Madrid</Address1><Address3>28041</Address3><Contacts/></Site><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Finland"><Sites><Site><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Helsinki</Address1><Address3>FIN-00290</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>Novartis Investigative Site</Name><Address1>Clichy Cédex</Address1><Address3>92118</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Lille Cedex</Address1><Address3>59020</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Montpellier</Address1><Address3>34298</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Paris Cedex 15</Address1><Address3>75908</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Strasbourg</Address1><Address3>67098</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Toulouse Cedex 9</Address1><Address3>31059</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Villejuif Cedex</Address1><Address3>94805</Address3><Contacts/></Site><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><Contacts/></Site><Site><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Basingstoke</Address1><Address3>RG24 9NA</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Greece"><Sites><Site><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Athens</Address1><Address3>GR 11527</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Bologna</Address1><Address2>BO</Address2><Address3>40138</Address3><CountrySubDivision>BO</CountrySubDivision><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Milano</Address1><Address2>MI</Address2><Address3>20100</Address3><CountrySubDivision>MI</CountrySubDivision><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Milano</Address1><Address2>MI</Address2><Address3>20141</Address3><CountrySubDivision>MI</CountrySubDivision><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Perugia</Address1><Address2>PG</Address2><Address3>06132</Address3><CountrySubDivision>PG</CountrySubDivision><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Pisa</Address1><Address2>PI</Address2><Address3>56126</Address3><CountrySubDivision>PI</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Groningen</Address1><Address3>9713 GZ</Address3><Contacts/></Site><Site><Name>Novartis Investigative Site</Name><Address1>Rotterdam</Address1><Address3>3015 CE</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Sweden"><Sites><Site><RecruitmentStatus id="4">Completed</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Medicinsk information -Medical info</Name></Contact></Contacts></Site><Site><Name>Novartis Investigative Site</Name><Address1>Uppsala</Address1><Address3>SE-751 85</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Slovakia"><Sites><Site><Name>Novartis Investigative Site</Name><Address1>Bratislava</Address1><Address2>Slovak Republic</Address2><Address3>813 69</Address3><CountrySubDivision>Slovak Republic</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Cancer Center of Central Connecticut</Name><Address1>Southington</Address1><Address2>Connecticut</Address2><Address3> 6489</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Centers of the Carolinas</Name><Address1>Greenville</Address1><Address2>South Carolina</Address2><Address3> 29615</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Care and Research</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3> 63141</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>Duke University Medical Center</Name><Address1>Durham</Address1><Address2>North Carolina</Address2><Address3> 27710</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Eastern Connecticut Hematology and Oncology Associates</Name><Address1>Norwich</Address1><Address2>Connecticut</Address2><Address3> 6360</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts/></Site><Site><Name>Fox Chase Cancer Center</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3> 19111</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Greater Dayton Cancer Center</Name><Address1>Kettering</Address1><Address2>Ohio</Address2><Address3> 45409</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>H Lee Moffitt Cancer Center and Research Institute</Name><Address1>Tampa</Address1><Address2>Florida</Address2><Address3> 33612</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Hematology Oncology Services of Arkansas HOSA</Name><Address1>Little Rock</Address1><Address2>Arkansas</Address2><Address3> 72205</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts/></Site><Site><Name>Highlands Oncology Group, P.A.</Name><Address1>Fayetteville</Address1><Address2>Arkansas</Address2><Address3> 72703</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts/></Site><Site><Name>Hitchcock Medical Center</Name><Address1>Lebanon</Address1><Address2>New Hampshire</Address2><Address3> 3756</Address3><CountrySubDivision code="NH">New Hampshire</CountrySubDivision><Contacts/></Site><Site><Name>Indiana University Cancer Center</Name><Address1>Indianapolis</Address1><Address2>Indiana</Address2><Address3> 46202</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Kansas City Cancer Center - Southwest</Name><Address1>Overland Park</Address1><Address2>Kansas</Address2><Address3> 66210</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Louisiana State University Health Sciences Center</Name><Address1>Kenner</Address1><Address2>Louisiana</Address2><Address3> 70065</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts/></Site><Site><Name>Louisville Oncology Research Program</Name><Address1>Lousville</Address1><Address2>Kentucky</Address2><Address3> 40202</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts/></Site><Site><Name>M D Anderson Cancer Center</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3> 77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Mayo Clinic Division of Medical Oncology</Name><Address1>Rochester</Address1><Address2>Minnesota</Address2><Address3> 55905</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>Medical University of South Carolina - Hollings Cancer Center</Name><Address1>Charleston</Address1><Address2>South Carolina</Address2><Address3> 29425</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>NYU Cancer Institute</Name><Address2>New York</Address2><Address3> 10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Ocala Oncology</Name><Address1>Ocala</Address1><Address2>Florida</Address2><Address3> 34474</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Oncology, PC</Name><Address1>Stamford</Address1><Address2>Connecticut</Address2><Address3> 6902</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts/></Site><Site><Name>Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3> 90048</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Pacific Cancer Medical Center Inc</Name><Address1>Anaheim</Address1><Address2>California</Address2><Address3> 92801</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Sarah Cannon Research Institute</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3> 37203</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>Scott and White Hospital</Name><Address1>Temple</Address1><Address2>Texas</Address2><Address3> 76508</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>South Texas Cancer Center</Name><Address1>Corpus Christi</Address1><Address2>Texas</Address2><Address3> 78405</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>The University of Kansas Hospital</Name><Address1>Kansas City</Address1><Address2>Kansas</Address2><Address3> 66160</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>Tyler Cancer Center</Name><Address1>Tyler</Address1><Address2>Texas</Address2><Address3> 75702</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>UCLA - Jonsson Comprehensive Cancer Center</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3> 90095</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>US Oncology</Name><Address1>Arlington Heights</Address1><Address2>Illinois</Address2><Address3> 60005</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>US Oncology</Name><Address1>Indianapolis</Address1><Address2>Indiana</Address2><Address3> 46227</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>US Oncology</Name><Address1>Vancouver</Address1><Address2>Washington</Address2><Address3> 98684</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>US Oncology - Texas Oncology 12th Avenue</Name><Address1>Fort Worth</Address1><Address2>Texas</Address2><Address3> 76104</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>US Oncology - Texas Oncology P.A.</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3> 78731</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>US Oncology/Sammons Cancer Center</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3> 75246</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>USO</Name><Address1>Denver</Address1><Address2>Colorado</Address2><Address3> 80218</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>University Hospitals of Cleveland - Ireland Cancer Center</Name><Address1>Cleveland</Address1><Address2>Ohio</Address2><Address3> 44106</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Name>University of Arizona - Arizona Cancer Center</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><Address3> 85724</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>University of Colorada Health Sciences Center</Name><Address1>Aurora</Address1><Address2>Colorado</Address2><Address3> 80045</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>University of Iowa Medical Center</Name><Address1>Iowa City</Address1><Address2>Iowa</Address2><Address3> 52242</Address3><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts/></Site><Site><Name>University of Wisconsin Comprehensive Cancer Center</Name><Address1>Madison</Address1><Address2>Wisconsin</Address2><Address3> 53792</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts/></Site><Site><Name>Virginia Oncology Associates</Name><Address1>Norfolk</Address1><Address2>Virginia</Address2><Address3> 23502</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Washington University School of Medicine - Siteman Cancer Center</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3> 63110</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>York Oncology Hematology</Name><Address1>Albany</Address1><Address2>New York</Address2><Address3> 12208</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Care and Hematology Specialists of Chicagoland Niles</Name><Address1>Niles</Address1><Address2>Illinois</Address2><Address3>60714</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Centers of Connecticut Southington Location</Name><Address1>Southington</Address1><Address2>Connecticut</Address2><Address3>06489</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts/></Site><Site><Name>Cancer Centers of the Carolinas CC of C -Eastside</Name><Address1>Greenville</Address1><Address2>South Carolina</Address2><Address3>29615</Address3><CountrySubDivision code="SC">South Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Cedars Sinai Medical Center SC-2</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90048</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Central Indiana Cancer Centers CICC - South</Name><Address1>Indianapolis</Address1><Address2>Indiana</Address2><Address3>46227</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Dartmouth Hitchcock Medical Center Medical Oncology</Name><Address1>Lebanon</Address1><Address2>New Hampshire</Address2><Address3>03756</Address3><CountrySubDivision code="NH">New Hampshire</CountrySubDivision><Contacts/></Site><Site><Name>Duke University Medical Center Dept. of Duke Cancer Center</Name><Address1>Durham</Address1><Address2>North Carolina</Address2><Address3>27710</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Eastern Connecticut Hematology &amp; Oncology Associates Dept. of ECHO</Name><Address1>Norwich</Address1><Address2>Connecticut</Address2><Address3>06360</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts/></Site><Site><Name>Fox Chase Cancer Center</Name><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><Address3>19111-2497</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Name>Hematology Oncology PC Dept.of Hematology Oncology(2)</Name><Address1>Stamford</Address1><Address2>Connecticut</Address2><Address3>06902</Address3><CountrySubDivision code="CT">Connecticut</CountrySubDivision><Contacts/></Site><Site><Name>Hematology Oncology Services of Arkansas</Name><Address1>Little Rock</Address1><Address2>Arkansas</Address2><Address3>72205</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts/></Site><Site><Name>Highlands Oncology Group The Center for Chest Care</Name><Address1>Fayetteville</Address1><Address2>Arkansas</Address2><Address3>72703</Address3><CountrySubDivision code="AR">Arkansas</CountrySubDivision><Contacts/></Site><Site><Name>Indiana University Dept.of IndianaUniv.CancerCtr</Name><Address1>Indianapolis</Address1><Address2>Indiana</Address2><Address3>46202</Address3><CountrySubDivision code="IN">Indiana</CountrySubDivision><Contacts/></Site><Site><Name>Kansas City Cancer Center KCCC Business Office</Name><Address1>Overland Park</Address1><Address2>Kansas</Address2><Address3>66210</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Deptof LSU Health Sciences (2)</Name><Address1>New Orleans</Address1><Address2>Louisiana</Address2><Address3>70112</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts/></Site><Site><Name>Mayo Clinic - Rochester Division of Hematology</Name><Address1>Rochester</Address1><Address2>Minnesota</Address2><Address3>55905</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>New York Oncology Hematology, P.C. Dept. of New York Oncology. PC</Name><Address1>Albany</Address1><Address2>New York</Address2><Address3>12206</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>New York University Medical Center NYU Medical Center (2)</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10016</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Northwest Cancer Specialists Compass Oncology -BKM</Name><Address1>Vancouver</Address1><Address2>Washington</Address2><Address3>98684</Address3><CountrySubDivision code="WA">Washington</CountrySubDivision><Contacts/></Site><Site><Name>Norton Cancer Institute Clinical Research Program</Name><Address1>Louisville</Address1><Address2>Kentucky</Address2><Address3>40202</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts/></Site><Site><Name>Ocala Oncology Center Dept. of Ocala Oncology Center</Name><Address1>Ocala</Address1><Address2>Florida</Address2><Address3>34471</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Pacific Cancer Medical Center, Inc.</Name><Address1>Anaheim</Address1><Address2>California</Address2><Address3>92801</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Rocky Mountain Cancer Centers Dept of Rocky Mountain (2)</Name><Address1>Denver</Address1><Address2>Colorado</Address2><Address3>80218</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>Sammons Cancer Center - Texas Oncology Sammons Cancer Center (SC)</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75246</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>South Texas Institute of Cancer S. Tex Inst.- Corpus Christi</Name><Address1>Corpus Christi</Address1><Address2>Texas</Address2><Address3>78405</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Texas Oncology, P.A. Central Austin Cancer Center</Name><Address1>Austin</Address1><Address2>Texas</Address2><Address3>78731</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Texas Oncology, P.A. Forth Worth -- 12th Avenue</Name><Address1>Fort Worth</Address1><Address2>Texas</Address2><Address3>76104</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>The Center for Cancer Care and Research</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3>63141</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Name>Tyler Cancer Center</Name><Address1>Tyler</Address1><Address2>Texas</Address2><Address3>75702</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>University of Arizona / Arizona Cancer Center Deptof Uof A/Arizona Cancer(2)</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><Address3>85719</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>University of California at Los Angeles UCLA New SC Address</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90095</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>University of Colorado Dept. of Univ. of Colorado</Name><Address1>Aurora</Address1><Address2>Colorado</Address2><Address3>80045</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Name>University of Iowa Medical Center Internal Medicine</Name><Address1>Iowa City</Address1><Address2>Iowa</Address2><Address3>52242</Address3><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts/></Site><Site><Name>University of Kansas Cancer Center Deptof Uof Kansas CancerCenter</Name><Address1>Kansas City</Address1><Address2>Kansas</Address2><Address3>66160</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site><Site><Name>University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>University of Wisconsin / Paul P. Carbone Comp Cancer Center GI Oncology Research Center</Name><Address1>Madison</Address1><Address2>Wisconsin</Address2><Address3>53792</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts/></Site><Site><Name>Virginia Oncology Associates VOA - Lake Wright</Name><Address1>Norfolk</Address1><Address2>Virginia</Address2><Address3>23502</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Name>Washington University School Of Medicine-Siteman Cancer Ctr Division of Oncology</Name><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3>63110</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pancreas tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8073">Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8076">Subjects with Pancreatic Endocrine Tumors (PETs)</PatientSegment><SubSegments><SubSegment id="8085">Subjects with pancreatic neuroendocrine tumor (NET)</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8079">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Neuroendocrine tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9891">Subjects with Carcinoid Tumor</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9903">Subjects with Well Differentiated (Low &amp; Intermediate-grade) NET</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9933">Subjects with Advanced/Metastatic Neuroendocrine Tumor</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9935">Subjects with Unresectable Neuroendocrine Tumor</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9943">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10845">Subjects with Stage IV Neuroendocrine Tumor</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00412061</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier>2006-004507-18</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Neuroendocrine tumor" id="11643"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Neuroendocrine tumor" id="11680"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pancreas tumor" id="13352"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pancreas tumor" id="13354"><Endpoint>Assessment of Disease Progression</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Neuroendocrine tumor" id="11640"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Neuroendocrine tumor" id="11643"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Neuroendocrine tumor" id="11644"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Neuroendocrine tumor" id="11645">Assessment of objective response rate (ORR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Neuroendocrine tumor" id="11666"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Neuroendocrine tumor" id="11668">Assessment of markers of proliferation</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Neuroendocrine tumor" id="11687"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13344"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13352"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13354"><Endpoint>Assessment of Disease Progression</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13356"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13357">Assessment of objective response rate (ORR)</SubEndpoint><SubEndpoint disease="Pancreas tumor" id="13359">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Pancreas tumor" id="13360">Assessment of Complete Response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13405"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13433"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13434">Assessment of serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13435"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13450"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13456"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13460"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Neuroendocrine tumor" id="11685"><Endpoint>Assessment of Disease Progression</Endpoint></OtherEndpoint><OtherEndpoint disease="Neuroendocrine tumor" id="11688"><Endpoint>Assessment of adverse events</Endpoint></OtherEndpoint><OtherEndpoint disease="Neuroendocrine tumor" id="11705"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Neuroendocrine tumor" id="11708">Assessment of Anti-tumor Activity</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Pancreas tumor" id="13344"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></OtherEndpoint><OtherEndpoint disease="Pancreas tumor" id="13435"><Endpoint>Assessment of adverse events</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Neuroendocrine tumor" id="7320"><Criterion>Subjects with Carcinoid Tumor</Criterion></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7329"><Criterion>Subjects with Well Differentiated (Low &amp; Intermediate-grade) NET</Criterion></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7334"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7342"><Criterion>Subjects with Stage IV Neuroendocrine Tumor</Criterion></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7344"><Criterion>Subjects with Unresectable Neuroendocrine Tumor</Criterion></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7345"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="7347">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Neuroendocrine tumor" id="7375"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8817"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8818"><Criterion>Subjects with Pancreatic Endocrine Tumors (PETs)</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8819">Subjects with pancreatic neuroendocrine tumor (NET)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8822"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8824">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="8853"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Neuroendocrine tumor" id="8912"><Criterion>Subjects with Poorly Differentiated (High-grade) NET</Criterion></Exclusion><Exclusion disease="Neuroendocrine tumor" id="8928"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Neuroendocrine tumor" id="8929"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Neuroendocrine tumor" id="8948"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="8953">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Neuroendocrine tumor" id="8956"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Neuroendocrine tumor" id="8958">Subjects with history of targeted therapy</SubCriterion><SubCriterion disease="Neuroendocrine tumor" id="8962">Subjects with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Neuroendocrine tumor" id="8964"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10377"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10378"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10397"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10399">Subjects with hypersensitivity/contraindication to targeted therapy agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10405"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10407">Subjects with history of targeted therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10412"><Criterion>Subjects with History of Treatment with Non-anticancer Drugs</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="11232"><Criterion>Subjects With Histological Subtypes Of Pancreatic Cancer</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2008-09-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>21.03 Months</EnrollmentPeriod><EnrollmentRate>20.40 Patients/Month</EnrollmentRate><DateFirstReceived>2006-12-13T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-10-03T12:41:24Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-09-09T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="315541"><TitleDisplay>Determination of mgso4 infusion effect for treatment of patient with acute pulmonary edema arrived rasol and sina hospital from khordad 1391 to khordad 1392</TitleDisplay><TitleOfficial>Determination of mgso4 infusion effect for treatment of patient with acute pulmonary edema arrived rasol and sina hospital from khordad 1391 to khordad 1392</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT201203089235N1</Identifier><Identifier type="Secondary Organisational">130/272/د/91</Identifier></Identifiers><Indications><Indication id="3546">Pulmonary edema</Indication></Indications><BiomarkerNames><BiomarkerName id="1913" role="Therapeutic effect marker" type="Physiological">Arterial oxygen saturation</BiomarkerName><BiomarkerName id="10260" role="Therapeutic effect marker" type="Physiological">Respiratory frequency</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>MgSo4</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1043016" type="Company"><TargetEntity id="5035525669" type="organizationId">Tehran University of Medical Sciences and Health Services</TargetEntity></SourceEntity><SourceEntity id="3546" type="ciIndication"><TargetEntity id="J81" type="ICD10"/><TargetEntity id="10037423" type="MEDDRA"/><TargetEntity id="D011654" type="MeSH"/><TargetEntity id="-147948730" type="omicsDisease"/><TargetEntity id="231" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043016">Tehran University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Infants (6-23 months)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2012-06-05T00:00:00Z</DateStart><DateChangeLast>2017-10-16T10:39:36Z</DateChangeLast><DateAdded>2017-10-16T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tehran university medical scince</Affiliation><Email>smzz592000@yahoo.com</Email><Name>Dr.Seyyed Mahdi Zia Ziabari M.D</Name><Phone>00982166525327 00989111375056</Phone></Contact><Contact type="Scientific contact"><Affiliation>Tehran university medical scince</Affiliation><Email>hafezimoghadam@yahoo.com</Email><Name>Dr.Peyman Hafezi Moghadam</Name><Phone>00982166525327 00989123478773</Phone></Contact><Contact type="Public contact"><Affiliation>Tehran university medical scince</Affiliation><Email>smzz592000@yahoo.com</Email><Name>Dr.Seyyed Mahdi Zia Ziabari M.D</Name><Phone>00982166525327 00989111375056</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient with acute pulmonary edema&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Presence of mgso4 side effects&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Hospitalization duration: compare of hospitalization duration in two groups</Description><Timeframe>For 6 h after trial initation</Timeframe></Measure><Measure><Description>Necessary for intubation: compare of incidence of dysrhytmia that demand treatment in two groups</Description><Timeframe>For 6 h after trial initation</Timeframe></Measure><Measure><Description>Improvement both SaO2 and dyspnea score(verbal quantitative scale) in 6 h after treatment initiation: compare of Sao2 improvement &gt; 94% and dyspnea score (by verbal quantitative scale pathway) for 6 h after treatment initiation in two groups</Description><Timeframe>For 6 h after trial initation</Timeframe></Measure><Measure><Description>Dysrhythmia incidence that should be treat in ED: compare of demand to intubation in two groups</Description><Timeframe>For 6 h after trial initation</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Decrease respiratory rate under 8/min: account respiratory rate in 1 min</Description><Timeframe>For 6 h from tretment initation</Timeframe></Measure><Measure><Description>Diminish of deep tendon reflex: monitoring of deep tendon reflex</Description><Timeframe>For 6 h after treatment initation</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;In this randomized single-blind trial, goal is whether that MgSo4 infusion results in decreased hospitalization duration, decreased intubation, decreased dysrhythmia incidence that should be treat in ED, improvement both SaO2 and dyspnea score (verbal quantitative scale) in 6 h after treatment initiation. &lt;br/&gt;Primary outcome measure are MgSo4 infusion in decreased hospitalization duration, decreased intubation, decreased dysrhythmia incidence that should be treat in ED, improvement both SaO2 and dyspnea score(verbal quantitative scale) in 6 h after treatment initiation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Pateints with acute cardiac pulmonary edema will be  randomized in two groups   after  explaining about trial and side effect of Mgso4 infusion. Both the groups  will start treatment by o2 until o2Sat of patient &amp;gt; 94% (minimum by 4 lit/min o2), plus Amp lasix 1 mgr/kg and Amp nitroglycerin 5 microg/min started and titrated 5 microg/min if patients blood pressure permitted, and Amp morphine sulfate 0.05 mg/kg for attention of patient blood pressure (preferly systolic blood pressure &amp;gt; 90 mmhg).these treatment are basic treatment of acute pulmonary edema.&lt;br/&gt;Patients will receive  1 g Mgso4 in 100 cc normal saline or 100 cc normal saline infused for 20 min as placebo.&lt;br/&gt;In both groups patients will receive loop diuretics or thiazides in last month ago. If  intervention patients show symptoms of Mgso4 toxicity (eg: patella areflexia or pulmonary depression) or with renal failure, exit this group.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Rasoul and Sina hospital</Name><Address1>Gulan</Address1><Address2>4144756779</Address2><CountrySubDivision>4144756779</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Seyyed Mahdi Zia Ziabari M.D</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT201203089235N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other respiratory disease" id="43004"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other respiratory disease" id="43449"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other respiratory disease" id="43465"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Other respiratory disease" id="43466">Length of hospital stay (LOS)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Other respiratory disease" id="43718"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other respiratory disease" id="43449"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other respiratory disease" id="43465"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other respiratory disease" id="43465"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other respiratory disease" id="32992"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other respiratory disease" id="24054"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other respiratory disease" id="24309"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2013-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>12.87 Months</EnrollmentPeriod><EnrollmentRate>3.11 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-10-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="99062"><TitleDisplay>Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation</TitleDisplay><TitleOfficial>Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Yes</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00297830</Identifier><Identifier type="Secondary Organisational">CZOL446H104</Identifier><Identifier type="Organisational Study">AAAB2324</Identifier><Identifier type="Trial Acronym">CTX</Identifier></Identifiers><Indications><Indication id="3443">Bone resorption</Indication></Indications><BiomarkerNames><BiomarkerName id="483" role="Therapeutic effect marker" type="Proteomic">Collagen type I trimeric cross-linked peptide</BiomarkerName><BiomarkerName id="3374" role="Therapeutic effect marker" type="Physiological">Bone mineral density</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>alendronic acid</Name><Drug id="2472">alendronic acid</Drug></Intervention><Intervention type="InterventionPrimary"><Name>zoledronic acid</Name><Drug id="2765">zoledronic acid</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2472">alendronic acid</Drug><IndicationsPioneer/><Companies><Company><Company id="20559">Columbia University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2765">zoledronic acid</Drug><IndicationsPioneer/><Companies><Company><Company id="20559">Columbia University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="23137">Novartis AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2472" type="Drug"><TargetEntity id="139212" type="siDrug">Alendronic acid sodium salt</TargetEntity></SourceEntity><SourceEntity id="2765" type="Drug"><TargetEntity id="144428" type="siDrug">Zoledronic acid monohydrate</TargetEntity></SourceEntity><SourceEntity id="20559" type="Company"><TargetEntity id="4296376980" type="organizationId">Columbia University</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="3443" type="ciIndication"><TargetEntity id="D001862" type="MeSH"/></SourceEntity></CrossReferences><Phase>Phase 2/Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20559">Columbia University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="23137">Novartis AG</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="12596">Osteoclast inhibitor</Class><Class id="1545">Anticancer</Class><Class id="695">Metastasis inhibitor</Class><Class id="89">Bone resorption inhibitor</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="894">Liquid formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="776">Oral gel formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>111</PatientCountEnrollment><PatientCountEvaluable>111</PatientCountEvaluable><DateStart>2005-11-30T00:00:00Z</DateStart><DateEnd type="actual">2014-01-31T00:00:00Z</DateEnd><DateChangeLast>2018-12-05T11:52:54Z</DateChangeLast><DateAdded>2012-11-23T08:02:47Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Columbia University</Affiliation><Name>Elizabeth Shane, M.D.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;A man or woman, aged 20 to 70 years, of any race who has had a heart or liver transplant&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Hyperparathyroidism&lt;/li&gt;&lt;li&gt;Paget's disease&lt;/li&gt;&lt;li&gt;Hyperthyroidism&lt;/li&gt;&lt;li&gt;Cancer&lt;/li&gt;&lt;li&gt;Severe kidney disease&lt;/li&gt;&lt;li&gt;Intestinal disease&lt;/li&gt;&lt;li&gt;Active peptic ulcer disease&lt;/li&gt;&lt;li&gt;Current or past treatment for osteoporosis&lt;/li&gt;&lt;li&gt;Pregnancy or lactation&lt;/li&gt;&lt;li&gt;Severe oral/dental disease&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Percentage Change From Baseline in Total Hip Bone Mineral Density (BMD): BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer</Description><Timeframe>Baseline, 12 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months: BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer</Description><Timeframe>Baseline, 12 months</Timeframe></Measure><Measure><Description>Percentage Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at 12 Months: BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer</Description><Timeframe>Baseline, 12 months</Timeframe></Measure><Measure><Description>Serum n-telopeptide (%) change</Description><Timeframe>24 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, double-blind, placebo-controlled, two-year  study was  to compare the effectiveness and safety of &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronic acid&lt;/ulink&gt; with      &lt;ulink linkType="Drug" linkID="2472"&gt;alendronate&lt;/ulink&gt; in the prevention of bone loss after organ transplantation.  &lt;ulink linkType="Drug" linkID="2765"&gt;Zoledronic acid&lt;/ulink&gt; would be        given as a single intravenous infusion. &lt;ulink linkType="Drug" linkID="2472"&gt;Alendronate&lt;/ulink&gt; would  given as a weekly pill. Both are      expected to be very effective, but it is not known which one would  work best.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In October 2010, results were presented. Bone mineral density (BMD) at baseline was significantly higher (all p &amp;lt; 0.001) in the reference  group at the total hip (1.078 + 0.13 versus 0.923 + 0.14), lumbar spine  (1.123 + 0.15 versus 0.964 + 0.14), and femoral neck  (0.924 + 0.11 versus 0.793 + 0.12) [&lt;ulink linkType="Reference" linkID="1543162"&gt;1543162&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2012, the results were published. BMD was declined at the spine and hip (p &amp;lt; 0.001) in the reference group where as in the  randomized groups hip BMD was stable. BMD at spine was increased in the &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronate&lt;/ulink&gt; group did not change in the &lt;ulink linkType="Drug" linkID="2472"&gt;alendronate&lt;/ulink&gt; group. In between the groups, difference of  2.2% was observed in 12 months (p = 0.009) which favored &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronate&lt;/ulink&gt;. In heart transplant patients. In the &lt;ulink linkType="Drug" linkID="2472"&gt;alendronate&lt;/ulink&gt; group,  spine BMD was declined and in &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronate&lt;/ulink&gt; group it was increased (p &amp;lt; 0.001). In patients who underwent liver transplantion, spine BMD was increased comparably in both groups. C-telopeptide was lower in the &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronate&lt;/ulink&gt; group than in the &lt;ulink linkType="Drug" linkID="2472"&gt;alendronate&lt;/ulink&gt; group at 12 months [&lt;ulink linkType="Reference" linkID="1543182"&gt;1543182&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients      would  receive one dose of active &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronic acid&lt;/ulink&gt; during the first month after heart or liver      transplantation and weekly placebo &lt;ulink linkType="Drug" linkID="2472"&gt;alendronate&lt;/ulink&gt; pills or one dose of placebo &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronic acid&lt;/ulink&gt;      and weekly active &lt;ulink linkType="Drug" linkID="2472"&gt;alendronate&lt;/ulink&gt; pills for the first year after transplant.  Over two years,      patients would  provide blood samples on nine occasions. Bone density would be performed      four to five times and spine X-rays would  be performed twice.&lt;/para&gt;&lt;para&gt;This study includes two arms:&lt;br/&gt;Arm A: patients would  receive an infusion of active &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronic acid&lt;/ulink&gt; 5 mg during the first 4 weeks after transplantation. Placebo &lt;ulink linkType="Drug" linkID="2472"&gt;alendronate&lt;/ulink&gt; 70 mg qw would  be initiated at the same time as the first &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronic acid&lt;/ulink&gt; infusion.&lt;br/&gt;Arm B: patients would  receive an infusion of placebo during the first 5 weeks after transplantation. Active &lt;ulink linkType="Drug" linkID="2472"&gt;alendronate&lt;/ulink&gt; 70 mg qw would  be initiated at the same time as the placebo infusion.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="2472"&gt;alendronate&lt;/ulink&gt; 70 mg/week for the first year or a single infusion of &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronic acid&lt;/ulink&gt; 5 mg. Administration of both drugs was  initiated 26 +/-  8 days  after transplantation.  All the patients  received ergocalciferol 50,000 IU daily for 5 days before the  &lt;ulink linkType="Drug" linkID="2765"&gt;zoledronic acid&lt;/ulink&gt;/placebo infusion, immunosuppressive therapy (prednisone, calcineurin inhibitors), daily calcium (945 mg) and vitamin D (1000 IU) during the study. A non-randomized reference (REF) group of transplantation  recipients (n = 25) with BMD T scores  &amp;gt; -1.5 was  enrolled so as  to provide data on rates of bone loss in transplantation  recipients not treated with bisphosphonates (BP) [&lt;ulink linkType="Reference" linkID="1543162"&gt;1543162&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1543182"&gt;1543182&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="243623">alendronic acid</Intervention><Treatments><Treatment><Dose>70 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="411840">calcium</Intervention><Treatments><Treatment><Dose>945 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="243622">zoledronic acid</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Columbia University Medical Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10032</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Liver transplantation</Disease><PatientSegments><PatientSegment><PatientSegment id="634">Liver Transplant Recipients</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Heart transplantation</Disease><PatientSegments><PatientSegment><PatientSegment id="3340">Heart Transplant Recipients</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Osteoporosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7653">Subjects at risk of developing disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00297830</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Osteoporosis" id="13772"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Osteoporosis" id="13771">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Heart transplantation" id="46053"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Heart transplantation" id="5849">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Liver transplantation" id="46073"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Liver transplantation" id="4853">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Liver transplantation" id="4847"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Heart transplantation" id="5623"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Osteoporosis" id="13772"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Osteoporosis" id="13771">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Osteoporosis" id="13789"><Endpoint>Assessment of Bone Resorption Markers</Endpoint><SubEndpoints><SubEndpoint disease="Osteoporosis" id="13794">Serum and urinary collagen type I cross-linked N-telopeptide</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Heart transplantation" id="46053"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Heart transplantation" id="5849">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Liver transplantation" id="46073"><Endpoint>Assessment of Bone</Endpoint><SubEndpoints><SubEndpoint disease="Liver transplantation" id="4853">Assessment by Bone mineral density (BMD)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Liver transplantation" id="2517"><Criterion>Liver Transplant Recipients</Criterion></Inclusion><Inclusion disease="Liver transplantation" id="2536"><Criterion>Subjects Requiring/With Other Organ Transplants</Criterion></Inclusion><Inclusion disease="Heart transplantation" id="2902"><Criterion>Heart Transplant Recipients</Criterion></Inclusion><Inclusion disease="Heart transplantation" id="2918"><Criterion>Subjects Requiring/With Other Organ Transplants</Criterion><SubCriteria><SubCriterion disease="Heart transplantation" id="2922">Subjects receiving liver transplant in addition to another transplant</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Osteoporosis" id="8690"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Osteoporosis" id="13287">Subjects with organ transplantation</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Liver transplantation" id="3688"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Liver transplantation" id="3697"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Liver transplantation" id="3715"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Liver transplantation" id="3716">Subjects co-morbid with peptic ulcer disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Liver transplantation" id="3722"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Liver transplantation" id="3730">Subjects with endocrine diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Heart transplantation" id="4016"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Heart transplantation" id="4022"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Heart transplantation" id="4036"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Heart transplantation" id="4037">Subjects co-morbid with peptic ulcer disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Heart transplantation" id="4061"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Heart transplantation" id="4068"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Osteoporosis" id="10241"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Osteoporosis" id="10249">Subjects with premalignant/malignant condition</SubCriterion><SubCriterion disease="Osteoporosis" id="10808">Subjects co-morbid with bone diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Osteoporosis" id="10245"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Osteoporosis" id="10247"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Osteoporosis" id="10248"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Osteoporosis" id="10268"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2013-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>87.06 Months</EnrollmentPeriod><EnrollmentRate>1.27 Patients/Month</EnrollmentRate><DateFirstReceived>2006-02-27T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-11-23T08:02:47Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2014-04-09T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="updated"><Date>2016-11-26T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>